A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Phase: PHASE2
Conditions: Solid Tumors
Sponsor: Merck Sharp & Dohme LLC

Official Protocol Title:
NCT number:
Document Date:
NCT01190644
A Phase 2, Open-Label, Pharmacodynamic
Study to Evaluate the Effect of Sotatercept
(ACE-011) on Red Blood Cell Mass and
Plasma Volume in Subjects With Solid Tumors
05-Mar-2012

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
1
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
TITLE PAGE
– SUMMARY OF CHANGES –
AMENDMENT NO. 3
A PHASE 2, OPEN-LABEL, PHARMACODYNAMIC STUDY TO 
EVALUATE THE EFFECT OF SOTATERCEPT (ACE-011) ON 
RED BLOOD CELL MASS AND PLASMA VOLUME IN
SUBJECTS WITH SOLID TUMORS
INVESTIGATIONAL PRODUCT (IP):
SOTATERCEPT (ACE-011)
PROTOCOL NUMBER:
ACE-011-ST-001
ORIGINAL DATE:
01 FEBRUARY 2010
AMENDMENT No. 1 DATE
18 APRIL 2011
AMENDMENT No. 2 DATE
15 NOVEMBER 2011
AMENDMENT No. 3 DATE
05 MARCH 2012
EudraCT NUMBER:
Not Applicable
CELGENE IND NUMBER:
103362
Contact Information:
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
you, your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by law or regulations.  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by them.
Page 1 of 84
PPD
0895R0

Page 2 of 84
PPD
PPD
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
3
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
1.
JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
1. An ACE-011-ST-001 Investigator Update meeting was held on 12DEC11.  Attendees 
included all 3 current Investigators (Drs. D. Henry, S. Noga, C. Miller) as well as Dr. 
Jerry Spivak from Johns Hopkins University, along with representatives from both 
Celgene and collaborating partner Acceleron.
The group discussed whether it is necessary to continue requiring a chemotherapy
‘holiday’ during the first dosing cycle with sotatercept while the pre-/post-dose Red 
Blood Cell / Plasma Volume (RBC/PV) testing is performed. Under the current protocol 
(Amendment #2: Final 15NOV11), at the time of enrollment into the study (Day 1) 
through Day 28 of the Treatment Period, subjects must not be receiving any other 
concurrent cytotoxic chemotherapy for their cancer.  Once both RBC/PV tests have been 
completed, subjects can initiate chemotherapy as directed by the Investigator.  
The original design strategy was to have the RBC/PV test conducted during this break in 
chemotherapy dosing, minimizing the possible impact of how responsive the bone 
marrow might be due to chemotherapy; however, many patients pre-screened for the 
study have not developed anemia during this post-chemotherapy window in the range 
required for entry into the study (i.e., hemoglobin value between ≥ 8.0 to < 11.0 g/dL).  
Also, it was initially thought that the study would produce more uniform results across 
subjects by not allowing concomitant chemotherapy during the RBC/PV testing.  Dr. 
Spivak has advised that the administration of concomitant chemotherapy will not impact 
analysis on RBC/PV activity and changes in RBC mass or plasma volume will either be 
evident or not.
The group agreed that the study should be opened up to all metastatic solid tumor patients 
(whether or not receiving chemotherapy).
2. Other administrative changes were also incorporated and are outlined in Section 2 
Itemized Changes.
Page 3 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
2.
ITEMIZED CHANGES
Text Modification Key:
Deleted Text
Added Text
Unchanged Text
2.1.
Section:  PROTOCOL SUMMARY (Pages 5-6)
Revised Text:
Objectives
_  _  _  _  _  _  _  _  _  _  _
The exploratory objectives are:
To evaluate treatment-related biomarkers
To evaluate the change in precursors in the bone marrow precursorsand blood
To measure gene expression levels in hematopoiesis
To evaluate pharmacokinetics of ACE-011
Study Design
_  _  _  _  _  _  _  _  _  _  _
ACE-011 (35 mg subcutaneous [SC] dose) will be administered to each subject who will be their 
own internal control with a pre-ACE-011 and post-ACE-011 RBC/PV test.  The measures for 
analysis of the RBC and hematopoietic effect are lab-related and nuclear scan-related and 
therefore not subject to biased results.  Subjects may receive up to a total of three doses of ACE-
011 during the study. (Study Day 1, 43, and 85).
At the time of enrollment into the study (Day 1) through Day 28 of the Treatment Period, 
subjects must not be receiving any other concurrent cytotoxic chemotherapy for their cancer.  
Once both RBC/PV tests have been completed, subjects can initiate chemotherapy as directed by 
the Investigator.  Subjects can then continue to receive up to two additional doses of ACE-011 at 
Day 43 and Day 85.
_  _  _  _  _  _  _  _  _  _  _
Study Treatments
Each 35 mg dose of ACE-011 will be administered as a subcutaneous injection given in the 
upper arm or thigh.
Subjects will be enrolled and receive their first dose of ACE-011 on study Day 1.  Up to two 
additional doses of ACE-011 will be administered every 42 days during the Treatment Period 
Page 4 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
(Day 43 and Day 85).  At the time of enrollment into the study (Day 1) through Day 28 of the 
Treatment Period, subjects must not be receiving any other concurrent cytotoxic chemotherapy 
for their cancer.  Once both RBC/PV tests have been completed, subjects can initiate 
chemotherapy as directed by the Investigator.  Subjects can then continue to receive up to two 
additional doses of ACE-011 at Day 43 and Day 85.
Rationale:
Language removed from protocol requiring no concurrent cytotoxic chemotherapy at the time of 
enrollment (Day 1) through Day 28 of the Treatment Period.  This will allow all metastatic solid 
tumor patients (whether or not receiving chemotherapy) to be evaluated for inclusion in the 
study.
Administrative change regarding precursor evaluation in bone marrow and blood.
Page 5 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
2.2.
Section 1:  INTRODUCTION (Page 14)
Revised Text:
The chemical structure of ACE-011 is composed of a disulfide-linked, glycosylated, dimeric 
protein.  ACE-011 competes with the activin receptor IIA that binds a number of TGF-β 
superfamily ligands including activin, myostatin (growth differentiation factor [GDF]-8), and 
GDF-11, preventing the biological activities of these ligands.
ACE-011 avidly binds to activin A with a binding coefficient (Kd) of approximately 8.9 pM and 
prevents its binding to endogenous receptors, thereby inhibiting biological effects of activin.
_  _  _  _  _  _  _  _  _  _  _
While the mechanism(s) underlying the stimulation effect of ACE-011 on erythropoiesis are not 
yet fully understood, it is hypothesized that a blockade of ActRIIA receptor signaling 
impedesmay effect the terminal differentiation step in later stages of erythropoiesis to allow 
additional rounds of erythroid cell replication before cells enter the terminal differentiation 
phase.  The result isfor a substantial increase in mature erythrocytes released into 
circulation.hemoglobin and hematocrit.  Since this proposed mechanism is likely different from 
that of known anemia agents, ACE-011 may provide a different clinical profile in the treatment 
of chemotherapy-induced anemia (CIA).
_  _  _  _  _  _  _  _  _  _  _
Activin BiologyReceptor Signaling
The activins (A-E) are a group of proteins that form dimers and heterodimers.  All are part of the 
TGF-Betaβ protein superfamily.  The first described activin, activin A, was initially identified as 
a gonadal differentiation factor involved in modulating follicle stimulating hormone (FSH) 
secretion from the pituitary (Ying, 1988).  Subsequently, the pleiotropic nature of activin A has 
become more apparent (Woodruff, 1998).  There is a growing body of data suggesting a role for 
activins in bone remodeling, specifically as a negative regulator of bone growth (Perrien, 2007).  
Before the two molecules were shown to be identical (Rivier, 1985), activinActivin A was 
alsoinitially described as an erythroid differentiation factor (EDF), aeffecting the maturation and 
differentiation of red blood cellsRBCs (Murata, 1988).  The mechanism(s) by which aActivin A 
influences erythropoiesis remains under investigation and, in fact, there are data from studies in 
vitro and in animalsvivo studies that support erythropoiesis-stimulatory (Shiozaki, 1992; 
Shiozaki, 1989) and erythropoiesis-inhibitory effects (Nakao, 1991).
At the cellular level, the activins bind initially to the The high-affinity Type IIActRIIA receptor.
binds to a number of ligands in the TGF- β superfamily including activins A and B, myostatin 
and other GDFs as well as a number of the bone morphogenetic protein (BMP) family.  The 
ligand-bound ActRIIA then recruits the low-affinity Ttype I receptor (ActRIA or activin-like 
kinase [ALK-4).  The]) and then the receptor heterocomplex, through its cytoplasmic protein 
kinase activity, then activates the Smad signaling cascade to eventually influence nuclear 
transcriptional factors (Chen, 2002; Mathews, 1994).  The competitive binding of activins in the 
blood and tissues by the ACE-011sotatercept soluble fusion protein can result in inhibition of the
ActRIIA receptor signaling pathway by impeding biological processes attributed to these 
pleiotropic proteins.
Page 6 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
The activin signaling pathway has also been attributed to erythroid differentiation and has been 
reported to have proerythrocytic effects and to induce terminal differentiation of RBCs.  
Inhibition of activin may lead to increases in proliferation of the erythroid lineage.  Based on its 
pharmacologic effects, ACE-011 is being developed for the treatment of bone loss associated 
with various disease states (e.g., osteoporosis and treatment of osteolytic lesions in patients with 
multiple myeloma), as well as the treatment of anemia associated with a variety of disorders, 
such as chemotherapy induced anemia.
Rationale:
Revisions made based on current understanding about ACE-011 mechanism of action.
Page 7 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
8
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
2.3.
Section 2:  STUDY OBJECTIVES (Page 25)
Revised Text:
2.3.
Exploratory Objectives
To evaluate treatment-related biomarkers
To evaluate the change in precursors in the bone marrow precursorsand blood
Rationale:
Administrative change.
Page 8 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
9
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
2.4.
Section 3:  STUDY ENDPOINTS (Page 26)
Revised Text:
3.3.
Exploratory Endpoint(s)
Change in bone mineral density (BMD)
Changes in serum bone specific alkaline phosphatase (BSAP) and urinary N-
telopeptide (uNTX) and other soluble or cellular biomarkers that may be altered in 
response to ACE-011
Measurement of erythroid pre-cursors in bone marrow including burst forming units 
(BFU-E) and erythroid colony forming units (CFU-E)and blood using flow cytometry
Measurement of gene expression profiles in mononuclear cells isolated from bone 
marrow
Concentrations of ACE-011 in serum
Rationale:
Administrative change.
Page 9 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
10
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
2.5.
Section 4:  OVERALL STUDY DESIGN (Pages 26-28)
Revised Text:
4.1.
Study Design
This is a phase 2, open-label, pharmacodynamic study to measure the change in red blood cell 
mass and plasma volume following one 35 mg SC dose of ACE-011 in subjects with solid 
tumors.  No fewer than 10 subjects will be enrolled into the study.
ACE-011 (35 mg SC dose) will be administered to each subject who will be their own internal 
control with a pre-ACE-011 and post-ACE-011 RBC/PV test.  The measures for analysis of the 
RBC and hematopoietic effect are lab-related and nuclear scan-related and therefore not subject 
to biased results.  Subjects may receive up to a total of three doses of ACE-011 during the study.
(Study Day 1, 43, and 85).
At the time of enrollment into the study (Day 1) through Day 28 of the Treatment Period, 
subjects must not be receiving any other concurrent cytotoxic chemotherapy for their cancer.  
Once both RBC/PV tests have been completed, subjects can initiate chemotherapy as directed by 
the Investigator.  Subjects can then continue to receive up to two additional doses of ACE-011 at 
Day 43 and Day 85.
Rationale:
Language removed from protocol requiring no concurrent cytotoxic chemotherapy at the time of 
enrollment (Day 1) through Day 28 of the Treatment Period.  This will allow all metastatic solid 
tumor patients (whether or not receiving chemotherapy) to be evaluated for inclusion in the 
study.
Page 10 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
11
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Revised Text:
4.1.1.
ACE-011 Dose Modification Rules
_  _  _  _  _  _  _  _  _  _  _
Table 2:
Dose Reduction and Modification Guidelines
NCI Toxicity 
Grade
Event
Action
_  _  _  _  _  _  _  _  _  _  _
For Hemoglobin 11 g/dL
_  _  _  _  _  _  _  _  _  _  _
Hgb > 2 g/dL increase 
sustained for a 28-day 
period from last dose

Dose delay1

Hold dose for one treatment visit

Re-evaluate Hgb & BP prior to resuming treatment

Resume dosingIf Hgb < 11 g/dL and hypertension < 
SBP 150 mmHg and < DBP 100 mmHg at the next 
scheduled visit, resume dosing – one level dose 
reduction (See Table 3)
Hgb > 3 g/dL increase 
sustained for a 28-day 
period from last dose

Dose delay1

Hold dose for one treatment visit

Re-evaluate Hgb & BP prior to resuming treatment

Resume dosingIf Hgb < 11 g/dL and hypertension < 
SBP 150 mmHg and < DBP 100 mmHg at the next 
scheduled visit, resume dosing – two level dose 
reduction (See Table 3)
Rationale:  
Based on review / recommendation received from FDA on 22FEB12 regarding protocol 
Amendment #1 (Final: 18APR11), for Amendment #3, in-text Table 2 updated to include 
clarification language regarding hemoglobin and blood pressure levels required in order to 
resume dosing at next scheduled visit, along with appropriate dose level reduction.
Page 11 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
12
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
2.6.
Section 5.
TABLE OF EVENTS (Page 34)
Revised Text:
Table 4:
ACE-011 RBC/PV Table of Events (Continued)
Assessments
Screening 
Period
Treatment (Tx) Period
Tx
DC
Follow-Up 
Period
Study 
DC
D-28
to D-1
D1 a
(±1d)
D3
(±1d)
D7
(±1d)
D14
(±2d)
D21
(±2d)
D29
(±2d)
D43a
(±3d)
D57
(±3d)
D71
(±3d)
D85a
(±3d)
D99
(±3d)
D113
(±3d)
D127
(±3d)
D155
(±7d)
D183
(±7d)
D211
(±7d)
_  _  _  _  _  _  _  _  _  _  _
Biomarkers in blood and urine j
X
-
-
-X
-
-
X
-
X
-
X-
-
X
X
X
-
X
Rationale:
The current protocol includes the first biomarker sample collected at the Screening Visit (prior to dosing with ACE-011).  The next 
sample to be collected is at Day 29 (28 days post first dose of ACE-011).  The Table of Events is being updated in order to get a post-
dose sample as early as possible during the first cycle of the Treatment Period since it is now believed that ACE-011 acts rapidly to 
mobilize erythroblast populations.  Given the current schedule of 28 days post-dose, this early activity might be missed if a sample is 
not collected earlier in the cycle.  Biomarker samples will continue to be collected at a total of eight time points throughout the study; 
however, the Day 85 sample has been replaced by the Day 7 sample.
Page 12 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
13
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
2.7.
Section 7:  STUDY POPULATION (Page 42)
Revised Text:
7.3.
Exclusion Criteria
_  _  _  _  _  _  _  _  _  _  _
3. Receiving cytotoxic chemotherapy treatment for metastatic cancer (currently or within 21 
days of study Day 1).  Concurrent trastuzumab (Herceptin), erlotinib (Tarceva), 
leuprolide acetate (Lupron) and / or hormonal treatments for metastatic cancer are 
permitted.
Rationale:
Exclusion criterion removed from protocol requiring no concurrent cytotoxic chemotherapy at 
the time of enrollment (Day 1) through Day 28 of the Treatment Period.  This will allow all 
metastatic solid tumor patients (whether or not receiving chemotherapy) to be evaluated for 
inclusion in the study.
Page 13 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
14
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
2.8.
Section 8:  DESCRIPTION OF STUDY TREATMENTS (Page 44)
Revised Text:
8.2.
Treatment Administration and Schedule
_  _  _  _  _  _  _  _  _  _  _
8.2.2.
Selection and Timing of Dosing for Each Patient
_  _  _  _  _  _  _  _  _  _  _
At the time of enrollment into the study (Day 1) through Day 28 of the Treatment Period, 
subjects must not be receiving any other concurrent cytotoxic chemotherapy for their cancer.  
Once both RBC/PV tests have been completed, subjects can initiate chemotherapy as directed by 
the Investigator.  Subjects can then continue to receive up to two additional doses of ACE-011 at 
Day 43 and Day 85.
Rationale:
Language removed from protocol requiring no concurrent cytotoxic chemotherapy at the time of 
enrollment (Day 1) through Day 28 of the Treatment Period.  This will allow all metastatic solid 
tumor patients (whether or not receiving chemotherapy) to be evaluated for inclusion in the 
study.
Page 14 of 84
0895R0

Sotatercept (ACE-011)
Summary of Changes ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
15
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
2.9.
Section 10:  STATISTICAL ANALYSES (Page 48)
Revised Text:
10.3.
Sample Size and Power Considerations
No fewer than ten subjects will be enrolled.  Assuming standard deviation of 5.5 mL/kg for the 
intra-patient difference in erythrocyte mass (Lim, 1989), this sample size will have aboutat least
90% power to detect 5.9 mL/kg pre- and post-ACE-011 therapy at one sided 5% significance 
level based on a paired t-test.
Rationale:
Administrative change.
Page 15 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
1
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
TITLE PAGE
A PHASE 2, OPEN-LABEL, PHARMACODYNAMIC 
STUDY TO EVALUATE THE EFFECT OF 
SOTATERCEPT (ACE-011) ON RED BLOOD CELL 
MASS AND PLASMA VOLUME IN SUBJECTS WITH 
SOLID TUMORS
INVESTIGATIONAL PRODUCT (IP):
SOTATERCEPT (ACE-011)
PROTOCOL NUMBER:
ACE-011-ST-001
DATE FINAL:
01 FEBRUARY 2010
AMENDMENT No. 1 DATE FINAL:
18 APRIL 2011
AMENDMENT No. 2 DATE FINAL:
15 NOVEMBER 2011
AMENDMENT No. 3 DATE FINAL:
05 MARCH 2012
EudraCT NUMBER:
Not Applicable
CELGENE IND NUMBER:
103362
SPONSOR NAME / ADDRESS
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
you, your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by law or regulations.  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by them.
Page 16 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
2
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION 
Contact Information:
Note:  The back-up 24 hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls  
Back-up 24 Hour Global Emergency Contact Call Center:  +1-877-501-7738
Page 17 of 84
PPD
0895R0

Page 18 of 84
PPD
PPD
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
4
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaration of Helsinki, ICH Good Clinical Practices 
Guidelines, and local regulations governing the conduct of clinical studies.
Page 19 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
5
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
PROTOCOL SUMMARY
Study Title
A phase 2, open-label, pharmacodynamic study to evaluate the effect of sotatercept (ACE-011)
on red blood cell mass and plasma volume in subjects with solid tumors.
Indication
Solid tumor malignancies
Objectives
The primary objective is:

To measure red blood cell mass (RBC) change and plasma volume (PV) following 
one dose of ACE-011 in cancer subjects with solid tumors
The secondary objectives are:

To measure plasma volume change following one dose of ACE-011 in cancer 
subjects with solid tumors

To evaluate the potential change in hematopoietic parameters

To evaluate the safety and tolerability of ACE-011
The exploratory objectives are:

To evaluate treatment-related biomarkers

To evaluate the change in precursors in the bone marrow and blood

To measure gene expression levels in hematopoiesis

To evaluate pharmacokinetics of ACE-011
Study Design
This is a mechanism of action (MOA) study of ACE-011 as a supportive care agent.  The 
primary objective is to measure the change in red blood cell mass (RBC) and plasma volume 
(PV) following one 35 mg dose of ACE-011 in subjects with solid tumors.  No fewer than ten
subjects will be enrolled and treated.
ACE-011 (35 mg subcutaneous [SC] dose) will be administered to each subject who will be their 
own internal control with a pre-ACE-011 and post-ACE-011 RBC/PV test.  The measures for 
analysis of the RBC and hematopoietic effect are lab-related and nuclear scan-related and 
therefore not subject to biased results.  Subjects may receive up to a total of three doses of ACE-
011 during the study (Study Day 1, 43, and 85).
The effect of ACE-011 will be analyzed based on all treated subjects.  Descriptive statistics will 
be provided for RBC mass and plasma volume pre- and post-ACE-011 therapy.  The pre- and 
post-difference will be compared based on a paired t-test.  In addition, descriptive statistics will 
be provided for secondary endpoints including bone or disease progression, bone mineral 
density, and bone biomarkers.
Page 20 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
6
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
An internal Data Monitoring Committee (DMC) will review summaries of the hematopoietic 
endpoints including RBC and PV 29 days post-dose of the last subject being enrolled.
Study Population
The study population includes subjects with a histologically confirmed diagnosis of a solid tumor 
malignancy documented by cytology or biopsy, with a presence of metastatic disease.  All 
subjects must have a baseline hemoglobin value between 8.0 to < 11.0 g/dL (80 to 
< 110 g/L).  Additionally, subjects must not have received any treatment with erythropoiesis-
stimulating agents (ESA) within 28 days of study entry and cannot be administered during the 
time between the pre-dose RBC / PV test and the post-dose RBC / PV test.  Intravenous (IV) iron 
replacement therapy for iron deficiency anemia is also not allowed during the study.
All subjects who qualify for enrollment into the study will enter the Treatment Period and 
receive their first subcutaneous 35 mg dose of ACE-011 on study Day 1.  A unique subject 
identification number will be manually assigned by the site staff to each subject entering the 
Treatment Period.
Length of Study
Each subject will be on the study for approximately eight months (including the Screening 
Period, the Treatment Period, and the Follow-Up Period).
The Treatment Period is approximately four months (up to 3 doses of ACE-011 to be 
administered every 42 days through study Day 126) with a post-treatment Follow-Up Period of 
three months from the subjects’ last dose of ACE-011 (through study Day 210).  Subjects who 
discontinue from the Treatment Period early will still continue to the Follow-Up Period for three 
months (84 days) from their last dose of ACE-011.
Study Treatments
Each 35 mg dose of ACE-011 will be administered as a subcutaneous injection given in the 
upper arm or thigh.
Subjects will be enrolled and receive their first dose of ACE-011 on study Day 1.  Up to two 
additional doses of ACE-011 will be administered every 42 days during the Treatment Period 
(Day 43 and Day 85).  
Subjects discontinued after Day 28 of the Treatment Period, having completed their second RBC 
mass and PV test, will not need to be replaced unless their hemoglobin did not increase after the 
ACE-011 dose.  Subjects discontinued for any cause prior to Day 28 or before their second 
RBC/PV test is completed will need to be replaced.
Overview of Efficacy (Pharmacodynamic) Assessments

Red blood cell mass / plasma volume
Overview of Safety Assessments

Complete physical examination including vital signs

Clinical laboratory evaluations (serum chemistry, hematology, absolute reticulocyte 
count)

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin
Page 21 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
7
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012

Serum erythropoietin

Vitamin B12 and serum folate levels

Thyroid function evaluation

Pregnancy testing (serum or urine beta-human chorionic gonadotropin levels [-
HCG] for females of childbearing potential [FCBP] only)

Electrocardiogram (ECG)

Anti-ACE-011 antibody assessment

Concomitant medications and procedures

Adverse events
Overview of Exploratory Assessments

Bone mineral density (BMD) (dual energy X-ray absorptiometry [DXA] scan to 
evaluate overall bone health in subjects with known bone metastases)

Bone marrow aspirate (BMA) (optional)

Bone biomarkers (anabolic bone biomarkers in blood and urine will be evaluated)

Pharmacokinetics
Page 22 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
8
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................5
1.
INTRODUCTION..................................................................................................14
2.
STUDY OBJECTIVES...........................................................................................24
2.1.
Primary Objective...................................................................................................24
2.2.
Secondary Objectives .............................................................................................24
2.3.
Exploratory Objectives ...........................................................................................24
3.
STUDY ENDPOINTS............................................................................................25
3.1.
Primary Endpoint(s) ...............................................................................................25
3.2.
Secondary Endpoint(s)............................................................................................25
3.3.
Exploratory Endpoint(s)..........................................................................................25
4.
OVERALL STUDY DESIGN ................................................................................26
4.1.
Study Design ..........................................................................................................26
4.1.1.
ACE-011 Dose Modification Rules.........................................................................26
4.2.
Study Design Rationale ..........................................................................................30
4.2.1.
Fixed Dose .............................................................................................................30
4.2.2.
Dosing Schedule.....................................................................................................30
4.3.
Study Duration .......................................................................................................30
5.
TABLE OF EVENTS.............................................................................................32
6.
PROCEDURES......................................................................................................35
7.
STUDY POPULATION.........................................................................................40
7.1.
Number of Subjects and Sites .................................................................................40
7.2.
Inclusion Criteria....................................................................................................40
7.3.
Exclusion Criteria...................................................................................................41
7.4.
Subject Withdrawal Criteria....................................................................................42
8.
DESCRIPTION OF STUDY TREATMENTS........................................................43
8.1.
Description of Investigational Product(s)................................................................43
8.2.
Treatment Administration and Schedule .................................................................43
8.2.1.
Selection of Dose for the Study...............................................................................43
8.2.2.
Selection and Timing of Dosing for Each Patient....................................................43
8.2.3.
Treatment / Study Discontinuation..........................................................................44
Page 23 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
9
8.3.
Method of Treatment Assignment...........................................................................44
8.4.
Packaging and Labeling..........................................................................................44
8.5.
Investigational Product Accountability and Disposal ..............................................44
8.6.
Investigational Product Compliance........................................................................44
9.
CONCOMITANT MEDICATIONS AND PROCEDURES....................................45
9.1.
Permitted Concomitant Medications and Procedures...............................................45
9.1.1.
General concomitant medication usage ...................................................................45
9.1.2.
Concomitant medication for anemia........................................................................45
9.1.2.1.
Iron supplementation ..............................................................................................45
9.1.2.2.
RBC transfusions....................................................................................................45
9.2.
Prohibited Concomitant Medications and Procedures..............................................45
9.3.
Required Concomitant Medications and Procedures................................................46
10.
STATISTICAL ANALYSES..................................................................................47
10.1.
Overview................................................................................................................47
10.2.
Study Population Definitions ..................................................................................47
10.3.
Sample Size and Power Considerations...................................................................47
10.4.
Background and Demographic Characteristics........................................................47
10.5.
Subject Disposition.................................................................................................47
10.6.
Efficacy Analysis....................................................................................................47
10.7.
Safety Analysis.......................................................................................................47
10.8.
Interim Analysis .....................................................................................................48
10.9.
Other Topics...........................................................................................................48
11.
ADVERSE EVENTS..............................................................................................49
11.1.
Monitoring, Recording and Reporting of Adverse Events .......................................49
11.2.
Evaluation of Adverse Events.................................................................................49
11.2.1.
Seriousness.............................................................................................................49
11.2.2.
Severity / Intensity..................................................................................................50
11.2.3.
Causality ................................................................................................................51
11.2.4.
Duration .................................................................................................................51
11.2.5.
Action Taken..........................................................................................................52
11.2.6.
Outcome.................................................................................................................52
11.3.
Abnormal Laboratory Values..................................................................................52
11.4.
Pregnancy...............................................................................................................52
Page 24 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
10
11.4.1.
Females of Childbearing Potential: .........................................................................52
11.4.2.
Male Subjects.........................................................................................................53
11.5.
Reporting of Serious Adverse Events......................................................................53
11.5.1.
Safety Queries ........................................................................................................53
11.6.
Expedited Reporting of Adverse Events..................................................................53
12.
DISCONTINUATIONS .........................................................................................55
13.
EMERGENCY PROCEDURES.............................................................................57
13.1.
Emergency Contact.................................................................................................57
13.2.
Emergency Identification of Investigational Products .............................................57
14.
REGULATORY CONSIDERATIONS...................................................................58
14.1.
Good Clinical Practice............................................................................................58
14.2.
Investigator Responsibilities ...................................................................................58
14.3.
Subject Information and Informed Consent.............................................................58
14.4.
Confidentiality........................................................................................................59
14.5.
Protocol Amendments.............................................................................................59
14.6.
Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................59
14.7.
Ongoing Information for Institutional Review Board / Ethics Committee................60
14.8.
Closure of the Study ...............................................................................................60
15.
DATA HANDLING AND RECORDKEEPING.....................................................61
15.1.
Data/Documents .....................................................................................................61
15.2.
Data Management...................................................................................................61
15.3.
Record Retention....................................................................................................61
16.
QUALITY CONTROL AND QUALITY ASSURANCE........................................63
16.1.
Study Monitoring and Source Data Verification......................................................63
16.2.
Audits and Inspections............................................................................................63
17.
PUBLICATIONS ...................................................................................................64
18.
REFERENCES.......................................................................................................65
19.
APPENDICES........................................................................................................66
Appendix A:  ECOG Performance Status Scale.........................................................................66
Appendix B:  National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4.0....................................................................67
Appendix C:  New York Heart Association - Classification of Heart Failure .............................68
Page 25 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
11
Appendix D:  Measurement of Red Blood Cell Mass and Plasma Volume.................................69
Page 26 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
12
LIST OF TABLES
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women:  
Hemoglobin Evaluation ..........................................................................................18
Table 2:
Dose Reduction and Modification Guidelines .........................................................27
Table 3:
ACE-011 Dose Reduction Levels ...........................................................................28
Table 4:
ACE-011 RBC/PV Table of Events ........................................................................32
Table 5:
ECOG Performance Status Scale ............................................................................66
Table 6:
New York Heart Association - Classification of Heart Failure ................................68
Page 27 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
13
LIST OF FIGURES
Figure 1:
Study Design ..........................................................................................................29
Page 28 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
14
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
1.
INTRODUCTION
The purpose of this study is to evaluate the effect of sotatercept (ACE-011) on red blood cell 
(RBC) mass and plasma volume (PV) in cancer subjects with solid tumors.
ACE-011 (ActRIIA-IgG1) is a recombinant human fusion protein consisting of the extracellular 
domain (ECD) of human activin receptor IIA (ActRIIA) linked to the human IgG1 Fc domain, 
which includes the heavy chain hinge and constant domains, CH2 and CH3.
The chemical structure of ACE-011 is composed of a disulfide-linked, glycosylated, dimeric 
protein.  ACE-011 competes with the activin receptor IIA that binds a number of TGF-β
superfamily ligands including activin, myostatin (growth differentiation factor [GDF]-8), and 
GDF-11, preventing the biological activities of these ligands.
In both single and multiple-dose phase 1 studies of ACE-011 in postmenopausal women, dose-
and time-dependent increases in hemoglobin (Hgb), hematocrit (HCT), and RBC levels were 
observed following ACE-011 treatment and remained elevated over the course of study.
Please refer to the Investigator Brochure for further information.
While the mechanism(s) underlying the stimulation effect of ACE-011 on erythropoiesis are not 
yet fully understood, it is hypothesized that a blockade of ActRIIA receptor signaling may effect 
the later stages of erythropoiesis to allow for a substantial increase in hemoglobin and 
hematocrit.  Since this proposed mechanism is likely different from that of known anemia agents, 
ACE-011 may provide a different clinical profile in the treatment of chemotherapy-induced 
anemia (CIA).
This study will provide information on the pharmacodynamic (PD) properties regarding the 
ability of ACE-011 to increase hemoglobin in subjects with CIA.
Activin Receptor Signaling
The activins (A-E) are a group of proteins that are part of the TGF-β protein superfamily.  There 
is a growing body of data suggesting a role for activins in bone remodeling, specifically as a 
negative regulator of bone growth (Perrien, 2007).  Activin A was initially described as erythroid 
differentiation factor (EDF), effecting the maturation and differentiation of RBCs (Murata, 
1988).  The mechanism(s) by which Activin A influences erythropoiesis remains under 
investigation and, in fact, there are data from in vitro and in vivo studies that support 
erythropoiesis-stimulatory (Shiozaki, 1992; Shiozaki, 1989) and erythropoiesis-inhibitory effects 
(Nakao, 1991).
The high-affinity ActRIIA receptor binds to a number of ligands in the TGF- β superfamily 
including activins A and B, myostatin and other GDFs as well as a number of the bone 
morphogenetic protein (BMP) family.  The ligand-bound ActRIIA then recruits the low-affinity 
type I receptor (ActRIA or activin-like kinase [ALK-4]) and then the receptor heterocomplex, 
through its cytoplasmic protein kinase activity, activates the Smad signaling cascade to 
eventually influence nuclear transcriptional factors (Chen, 2002; Mathews, 1994).  The 
competitive binding of activins in the blood and tissues by the sotatercept soluble fusion protein 
can result in inhibition of the ActRIIA receptor signaling pathway by impeding biological 
processes attributed to these pleiotropic proteins.
Page 29 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
15
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
ACE-011 is the soluble and tissue related ligand trap composed of the extracellular domain of 
the activin receptor ActRIIA.  The extracellular domain sequence of ActRIIA is completely 
conserved among numerous species including mouse, rat, cynomolgus monkey, and humans, 
thus mouse, rat, and cynomolgus monkeys have been considered relevant species for nonclinical 
evaluation of ACE-011; however, in order to reduce the potential immunogenicity in mice of the 
fully human molecule, ACE-011, and to maximize the opportunity to maintain exposures in 
chronic mouse models, a murine surrogate molecule was constructed by exchanging the human 
immunoglobulin Fc sequence portion of ACE-011 with its murine IgG2a homologue.  The 
resultant construct is referred to as RAP-011 (ActRIIA-mIgG2aFc), and is described in the 
pharmacology studies below.
Pharmacology Studies
RAP-011 was evaluated in a broad range of animal pharmacology studies to assess the effects of 
inhibition of activin A on the biological processes attributed to that regulatory protein.  RAP-011 
has been shown to have significant effects on the red cell compartment.  RAP-011 treatment of 
mice at 10, 30 and 50 mg/kg by intraperitoneal injection twice per week for 3 months resulted in 
a 16%-26% increase in RBC counts compared to control animals.  Rats treated with ACE-011 at 
doses of 0.3, 3, and 30 mg/kg once per week for 3 months showed RBC count increases of 6-
15% over control animals.  Finally, in cynomolgus monkeys treated with 10, 30 or 50 mg/kg of 
ACE-011 twice per month for 3 months, there was a 21%-24% increase in RBC counts 
compared to control animals.  In this study, the RBC count increase was apparent as early as 2 
weeks following the initial dose of ACE-011.
RAP-011 administered at 10 mg/kg to mice three days prior to administration of paclitaxel at 30 
mg/kg was sufficient to prevent decreases in RBC parameters typically seen three days later.  
Mice receiving paclitaxel alone had decreased hematocrit levels from 43% to 38% three days 
following treatment.  RAP-011 administered three days prior to paclitaxel injection was 
sufficient to keep the hematocrit levels above 42% at three days and up to two weeks following 
paclitaxel administration.  Therefore, prophylactic treatment with RAP-011 was able to prevent 
paclitaxel induced anemia in mice.
Toxicology
ACE-011 has been evaluated for toxicological effects in two species, Sprague-Dawley rats and 
cynomolgus monkeys.  The dose levels ranged from 0.3 to 30 mg/kg in rats and from 1 to 50 
mg/kg in monkeys.  These dose ranges were designed to support phase 1a single-dose levels of 
0.01 to 3.0 mg/kg IV as well as 0.03 and 0.1 mg/kg subcutaneously (SC) and phase 1b multiple 
doses of 0.1 to 2.0 mg/kg (monthly, SC).  Weekly dosing in animals was designed to provide 
continuous, but fluctuating serum concentrations of ACE-011, which would mimick a one-month 
dosing interval in humans.
ACE-011 dosing in preclinical animal toxicology studies resulted in expected pharmacodynamic 
effects of inhibition of FSH by the activin signaling pathway, such as effects on male gonadal 
tissues (testicular degeneration, decrease sperm counts and motility). In addition, the adrenal 
cortical lesions (necrosis or mineralization) observed in rats may be the result of interference of 
activin signaling on the developing adrenal gland. The pancreatic findings (zymogen granule
depletion and atrophy of pancreatic acini) were only observed in the 1-month rat study by the IV 
route of administration and were not associated with any clinical signs of pancreatic 
Page 30 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
16
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
insufficiency (abnormal stool, weight loss, etc.). Glomerular lesions (glomerulonephritis) were 
observed in both rats and monkeys in the 3-month SC studies that were presumed to be due to 
anti-drug antibody deposition. This presumption is supported by a robust anti-drug antibody 
response in rats (58% of animals positive for anti-ACE-011 antibodies). In monkeys, due to the 
high plasma concentrations of ACE-011 interfering with the immunogenicity assay, the true 
incidence of anti-drug antibodies could not be documented. In a chronic monkey study, the 
kidney lesions had changed to be more tubular in nature (tubulointerstitial nephritis) and may be 
due to off-target inhibition of BMP-7 in a setting of the exceedingly high concentrations of ACE-
011. A 9-month monkey study is ongoing to evaluate the effects of lower concentrations of 
ACE-011.
Initial studies utilized IV dosing to identify target organs while longer-term studies (3 months in 
rats; 3 and 6 months in monkeys) utilized SC dosing to mimic the intended dosing regimen for 
patients.  The expected pharmacologic effect, increased RBCs, Hgb, HCT and reticulocytes, was 
observed in all studies, presumably based on the ability of ACE-011 to inhibit activin.  A second 
expected pharmacologic effect of ACE-011, based on inhibition of activin, observed was the 
reversible reduction in sperm production and testicular tubular damage in rats.  Since male 
cynomolgus monkeys were sexually immature in these studies, it was not possible to monitor 
this effect in this species.
An adverse effect of ACE-011 was only observed on the adrenal gland and was only seen in rats, 
which was more pronounced in female rats. This toxicological observation may not be relevant 
for predicting effects in humans since adrenal toxicity was not seen in cynomolgus monkeys.  
Dose-limiting toxicity and no observable adverse effect levels (NOAELs) were primarily based 
on renal toxicity in both rats and monkeys.  There was some indication that kidney toxicity was 
an indirect effect, based on the formation of antibody/antigen complexes, but since these studies 
were not designed to investigate toxicological mechanisms, a definitive cause of renal 
impairment and renal damage was not determined.  Development of antibodies to ACE-011 was 
noted in all of these studies, which is an expected immune reaction in rats and monkeys dosed 
with a human protein.
The NOAELs from the 3-month SC studies were 3 and 30 mg/kg in rats and monkeys, 
respectively. Since the kidney findings were observed at all dose levels, a NOAEL was not 
identified in the 6-month monkey study.  
Summary of Clinical Experience
A011-01:  A Phase 1a Study in Healthy Postmenopausal Women
ACE-011 was first studied in a randomized, phase 1a, single dose, dose escalation study in 
healthy, post-menopausal females (Ruckle, 2009).  ACE-011 was diluted in normal saline 
administered as an IV infusion (over approximately 1 hour) or as a SC injection on Day 1.  Dose 
levels were 0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg IV and 0.03 and 0.1 mg/kg SC.  A total of 48 
subjects were enrolled; 5 active and 1 placebo at each of the IV and SC dose levels.  All subjects 
were followed for 4 months following a single dose administration.
The pharmacokinetics of ACE-011 was linear for all IV and SC doses.  Across IV doses ranging 
from 0.1 through 3.0 mg/kg, the mean clearance (CL) ranged from 0.092 to 0.128 mL/h/kg, the 
volume of distribution ranged from 73.7 to 110 mL/kg, and the mean t1/2 ranged from 23.7 to 
31.8 days, with no apparent dependence on dose.  After SC administration of 0.03 and 
Page 31 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
17
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
0.1 mg/kg, ACE-011 was completely absorbed, and the mean t1/2 was approximately 30 days, 
with no apparent dependence on dose.
The most commonly occurring treatment-emergent AEs (i.e., those occurring in more than 1 
subject in any treatment group) were headache, infusion site reaction, injection site hemorrhage, 
and toothache.  The majority of the injection site reactions and injection site hemorrhages were 
in the first IV cohort and were related to infiltration of the IV site.  The majority of treatment-
emergent AEs were mild in severity and were judged to be unrelated to ACE-011.  No deaths, 
serious AEs (SAEs), or AEs leading to discontinuation were reported.  Changes in RBCs, 
hemoglobin, reticulocytes, liver function tests, glucose, uric acid, amylase and lipase occurred in 
some subjects.  Mild, transient elevations in pancreas enzymes, liver enzymes, or glucose were 
reported as AEs in five subjects.
There were no clinically significant changes from baseline in vital signs, physical examination, 
endocrine function, or electrocardiogram (ECG) data.  Preservation of adrenal cortical function 
was monitored through evaluation of serum electrolytes (sodium and potassium levels) and 
through cortisol response to adrenocorticotropic hormone (ACTH) stimulation.
No clinically significant findings were observed at doses up to 3.0 mg/kg IV, and ACE-011 was 
well tolerated in healthy, post-menopausal female volunteers in single dose levels up to 
0.1 mg/kg SC and 3.0 mg/kg IV, the highest dose levels tested in this study.
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women 
ACE-011 was studied in a phase 1b, single-center, randomized, double-blind, placebo-
controlled, multi-dose, dose-escalating study to evaluate the safety, tolerability and 
pharmacodynamics of ACE-011 in healthy postmenopausal women.  Four cohorts of 10 subjects 
each were planned at the following dose levels:  0.1, 0.3, 1.0, and 2.0 mg/kg administered 
subcutaneously.  Within each cohort, subjects were to be randomized to either active or placebo 
treatment in an 8:2 ratio.  Subjects were to receive one SC injection of ACE-011 or placebo 
every 28 days for a total of 4 doses.  All subjects were to be followed for 12 weeks after the last 
dose.
The treatment phase of the study was terminated early after a dose-limiting pharmacodynamic 
effect was observed.  While on study, one subject in the 1.0 mg/kg cohort experienced an SAE of 
progressive and persistent hypertension that was attributed to a rapid and significant rise in Hgb 
and HCT levels.  Due to symptoms of headaches, nausea, eye pain, dizziness and vomiting 
approximately one week following the second dose, the subject was hospitalized for monitoring 
and evaluation of her hypertension.  The head magnetic resonance imaging (MRI), fundoscopy, 
and ECG performed were reported as normal and headache symptoms resolved following 
therapeutic phlebotomy.  The SAE resolved and the subject was discharged from the hospital the 
following day.  The hypertension was monitored closely and managed initially with 
antihypertensive medication.  The hypertension resolved by the end of the study without need of 
any antihypertensive medication.  The subject received aspirin prophylactically until the end of 
the study and continued taking ibuprofen as needed for headaches.  Further details can be found 
in the Investigator Brochure.
Based on the magnitude of the hematopoietic response, the Sponsor suspended dose escalation to 
the 2.0 mg/kg dose level and further dosing in all cohorts as a result of this dose-limiting 
pharmacodynamic effect at the 1.0 mg/kg dose level.  In total, 31 subjects were enrolled and 
Page 32 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
18
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
treated.  Dose levels of ACE-011 administered included 0.1, 0.3, and 1.0 mg/kg (Cohorts 1, 2, 
and 3 respectively).  All subjects randomized to active treatment in Cohort 1 received all 4 
planned doses of ACE-011.  Due to early discontinuation of study drug, subjects randomized to 
active treatment in Cohort 2 received 3 doses of ACE-011, and subjects randomized to active 
treatment in Cohort 3 received 2 doses of ACE-011.  Subjects randomized to placebo treatment 
received between 1 and 4 doses of study treatment.
In the analysis of the data, after the administration of the first dose, a dose and time dependent 
increase in hemoglobin, HCT, and RBC values were observed (see Table 1 below for changes in 
Hgb levels):
Table 1:
A011-02:  A Phase 1b Study in Healthy Postmenopausal Women:  
Hemoglobin Evaluation
Evaluation Time Point
Mean Change from Baseline (g/dL)
Placebo
N=7a
ACE-011
0.1 mg/kg
N=8
ACE-011
0.3 mg/kg
N=8
ACE-011
1.0 mg/kg
N=8
Baseline Mean, pre-Dose 1
13.20
13.11
13.30
12.71
Day 8
0.17
0.68
0.85
1.21
Day 15
-0.27
0.43
0.44
1.75
Day 29
0.27
0.61
1.21
2.68b
Day 36
0.56
0.64
1.89
2.96
Day 43
-0.02
0.89
1.21
2.85
Day 57
0.27
1.28
1.64 b
2.09
Day 64
0.53
1.11
2.49
2.21
Day 71
-0.10
1.34
2.09
1.66
Day 85
0.38
1.18 b
2.55
1.86
Day 92
0.00c
1.04
1.60 c
3.80 c
Day 99
-0.20
1.21
3.20 c
1.28 c
Day 113
-0.02
1.30
1.29
1.04
Day 141
0.30
0.95
0.34
2.30
Day 169
0.20 c
0.06
2.00 c
a The number of placebo subjects with data decreases over time as a result of the early discontinuation of the study 
(i.e., there were placebo subjects in each dosing cohort). There were seven placebo subjects with data at baseline, 
Days 8, 15, and 36; six subjects with data at Days 29, 43, 57, and 85; five subjects with data on Days 71 and 113; 
four subjects with data on Day 64; three subjects with data on Day 141; two subjects with data on Day 99; and one 
subject with data on Days 92 and 169.
b Number of doses administered per treatment group:  0.1 mg/kg 4 doses; 0.3 mg/kg 3 doses; 1.0 mg/kg 2 doses.  
Data beyond this study day are considered follow-up results.
c n=1
Page 33 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
19
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
No severe or life-threatening events were reported.  The most notable AEs were those related to 
increases in hematologic laboratory measures in the 1.0 mg/kg dose group:  hematocrit, 
hemoglobin, and RBC count.  AEs of increased hemoglobin and/or hematocrit were reported for 
seven of the eight subjects in this dose group.  These events were reported as mild or moderate 
elevations; all were considered probably related to study drug treatment.  Three of the subjects in 
the 1.0 mg/kg group with elevated hemoglobin levels underwent phlebotomies and all 
hemoglobin elevations were resolved by the end of the follow-up period.  No erythroid lineage 
AEs were reported in the 0.1 or 0.3 mg/kg treatment groups.
Headaches were common in all treatment groups with no dose response evident; most were mild.
Paresthesia and dizziness were reported more frequently in the ACE-011 groups, though the 
events were generally not considered drug related.  Other frequently reported events (e.g. fatigue, 
upper respiratory infection) did not appear to increase with dose and were generally mild.
Hemoglobin levels for all subjects with elevations had returned to within normal limits by the 
end of the study.
Adrenal cortical function was monitored through evaluation of serum electrolytes (sodium and 
potassium levels) and through cortisol response to adrenocorticotropic hormone (ACTH) 
stimulation.  All ACTH simulation test results were normal.
Pharmacokinetic (PK) results confirmed that ACE-011 is linear following the first SC doses of
all three dose levels tested, 0.1, 0.3, and 1.0 mg/kg.  The terminal half life (t1/2) of ACE-011 
following the last dose in all three dose groups was identical, with mean t1/2 being approximately 
23 days.  Based on the one-compartmental modeling, the mean CL/F ranged from 3.05 to 3.90 
mL/d/kg, the mean Vz/F (apparent volume of distribution) ranged from 97.47 to 103.03 mL/kg, 
and the mean t1/2 ranged from 20.92 to 23.34 days in all 3 dose levels, with no apparent 
dependence on dose.
Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry (DXA).  A 
dose-dependent increase in the BMD of the total hip from baseline to end of study was observed, 
with a significant and rapid increase of 2.4% in the 1.0 mg/kg dose group, compared to a 0.7% 
decrease in the placebo group.  BMD results for lumbar spine showed slight increases of 0.4% to 
1.0% from baseline to study end in all active treatment groups, compared with a 0.5% decrease 
in the placebo group.
A011-04:  A Phase 2a Study in Patients with Osteolytic Lesions of Multiple Myeloma / 
Preliminary Results
Study A011-04 was a phase 2a, multi-center, randomized, multiple-dose study to evaluate the 
safety, tolerability and efficacy of ACE-011 in subjects with osteolytic lesions of multiple 
myeloma (MM).  Safety evaluations included AEs, clinical laboratory tests, standard 12-lead 
electrocardiogram, vital signs, Eastern Cooperative Oncology Group (ECOG) performance status 
and physical examinations.  Additionally, the study included the assessment of biochemical 
markers of bone formation and resorption, skeletal related events (SREs), BMD by DXA, and 
bone pain by visual analog scale (VAS).
In this study, subjects were randomized in a 4:1 ratio to one of three dose levels of ACE-011 
(0.1, 0.3 and 0.5 mg/kg) or placebo, to be administered to subjects every 28 days by 
subcutaneous injection, for up to four doses over a 3-month period.  The test article was
Page 34 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
20
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
evaluated in combination with the anti-myeloma therapy of melphalan (4 mg/m2 on days 1-7), 
prednisolone (40 mg/m2 on days 1-7) and thalidomide (100 mg per day) (MPT).  The sites, 
Sponsor and Sponsor representatives were blinded to treatment assignment.
A total of 30 subjects were randomized and treated with ACE-011 or placebo.
One (1) subject died on 
 due to sudden death (including progression of disease).  
Relevant prior medical history included 
 
  The subject was taking 
prophylactically 
  The subject had received the first dose of 
ACE-011/placebo and started cycle 1 MPT on 
  The last study dose was 
administered on
.  On 
 the subject developed grade 2 blood 
pressure increase, which resolved with the subject’s blood pressure medication.  The following 
day 
 the subject’s blood pressure was reported to have returned to baseline.  
The subject then died on
, 18 days after last study dose, due to the described 
sudden death.  No autopsy was performed.  The Investigator assessed event causality as possibly 
related to ACE-011/placebo and probably related to MPT.
One SAE of atrial fibrillation with syncope was reported in a 
subject 
receiving 0.5 mg/kg of ACE-011, resulting in study discontinuation.  This was in a subject with 
prior history of 
.  On further review this subject’s inclusion into the 
study was a protocol violation.  The Investigator assessed event causality as unrelated to ACE-
011/placebo and possibly related to MPT.  
One SAE of prolonged hospitalization due to pneumonia, that was considered not related to 
ACE-011, was reported in a 
subject enrolled in the study.  On 
 four days after the first dose of ACE-011/placebo and the initial doses of melphalan, 
prednisolone and thalidomide (MPT), the subject presented with elevated temperatures up to 
39ºC, cough and fatigue.  Chest x-ray revealed a pneumonic infiltration in the lower lobe of the 
left lung resulting in prolonged hospitalization.  Treatment included moxifloxacin, doripenem, 
meropenem and fluconazole with resolution of the event.
The Investigator considered the event of pneumonia unrelated to ACE-011 and possibly related 
to MPT.
An SAE of leg pain was reported in a 
 and was found to have a pathological 
fracture of the right upper femoral bone approximately 2.5 months after last dose of ACE-
011/placebo, approximately 5 weeks after last dose of melphalan-prednisolone and one day after 
the last dose of thalidomide.  Radiologic evaluations demonstrated progressive bone tissue 
destruction at presentation.  The subject was casted, and then underwent coxal bandaging.  The 
event resolved with sequelae.  The Investigator considered the events of pain in the right leg and 
pathological fracture of the upper third of the right femur unrelated to ACE-011/placebo and 
unrelated to thalidomide (MPT).
The A011-04 study has been completed and final analysis of the data and completion of the 
clinical study report are ongoing.
Potential Risks for Human Use
Nonclinical studies to determine the safety of ACE-011 have been conducted in cynomolgus 
monkeys and Sprague Dawley rats.  Many of the observed effects in these studies were as a 
Page 35 of 84
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
21
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
result of the expected biologic activity of activin inhibition and can be summarized as a 
dose-dependent decrease in sperm count and motility secondary to FSH suppression as well as 
reversible increases in RBC parameters due to the effects on erythroid differentiation factor 
(activin).  
The most significant toxicity findings are listed below:  

Hematological findings (increase in RBC parameters – RBCs, Hgb, HCT) were 
observed across all studies.  Associated with the increase in RBC parameters were 
increases in reticulocytes and decreases in mean corpuscular hemoglobin (MCH) and 
mean corpuscular hemoglobin concentration (MCHC).  The increase in RBC 
parameters is an anticipated effect of ACE-011 treatment and is being targeted as a 
therapeutic intervention for conditions associated with anemia.  

In the 6- and 9-month monkey studies, glomerulonephritis and/or tubulointerstitial 
nephritis were observed in monkeys administered ≥ 10 mg/kg administered SC every 
2 or 4 weeks. At 2.6 mg/kg administered SC every 4 weeks for 9 months, kidney 
findings were limited to a single incidence of tubulointerstitial nephritis. The 
NOAEL in the 9-month study was considered to be 1 mg/kg every 4 weeks. Serum 
exposure in monkeys at the 1 mg/kg dose is estimated to be ~1.3-fold greater than the 
projected serum exposure in humans at the maximum proposed human dose of 61 mg 
every 6 weeks.  In the single- and multiple-dose studies in healthy postmenopausal 
women, there have been no changes in serum chemistry or urinalysis profiles 
suggestive of kidney injury.  Subjects administered ACE-011 should continue to be 
closely monitored.  

In the 9-month monkey study, treatment-related findings in the choroid plexus 
included:  perivascular accumulations of foamy macrophages and intimal thickening 
of small arteries and arterioles primarily at 10 mg/kg administered every 2 weeks as 
well as an increased incidence of small, focal aggregates of mononuclear 
inflammatory cells at all dosages. Findings at 1 mg/kg were limited to mononuclear 
cell infiltrates and were not adverse.  

Adrenal gland congestion or necrosis was observed in rats but not in monkeys.  The 
finding was more pronounced in female rats and appeared following either one month 
of IV dosing or 3 months of SC dosing.  Although the current data suggest adrenal 
toxicity may be specific to rats, the relevance of the adrenal findings to humans is 
uncertain.  

Elevations in liver enzymes (alanine aminotransferase [ALT], aspartate 
aminotransferase [AST], and/or alkaline phosphatase), as well as triglycerides, were 
observed sporadically in rats and monkeys treated with ACE-011.  There were no 
histological correlates in the liver, and often a dose-response relationship was not 
observed.  The relevance of these findings to ACE-011 treatment is uncertain; 
however, these endpoints will continue to be monitored in the clinic.  

Pregnancy and Lactation

Due to the potential for effects on hormones in the pituitary, including FSH, in 
addition to possible direct effects on fetus, there may be potential effects on the 
Page 36 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
22
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
fetus. Delays in fetal development (decreased fetal weights and delays in 
ossification) were observed at doses ≥15 mg/kg (15-fold greater on a mg/kg basis 
than the maximum proposed human dose of 60 mg every 6 weeks assuming a 60 
kg person). In addition, at 50 mg/kg (100-fold the maximum proposed human 
dose), there was an increase in late fetal death coupled with an overall increase in 
post-implantation loss and a reduction in live litter size, as well as an increase in 
the incidence of developmental variations of supernumerary ribs with 
corresponding increases and decreases in thoracic and lumber vertebrae, 
respectively. No fetal malformations were observed in this study at dosages up to 
50 mg/kg. The NOAEL for embryofetal development effects was 5 mg/kg 
(~5-fold greater than the maximum proposed human dose of 60 mg every 6 weeks 
assuming a 60 kg person) based on reduced fetal weights and associated delays in 
ossification.  Although the risks for embryofetal development effects are 
considered relatively low given the large safety margins, precautions should still 
be taken to protect females of childbearing potential. Nonclinical studies on 
breast milk have not been done.  

If ACE-011 is taken during pregnancy, a teratogenic effect in humans cannot be
ruled out.  Therefore, all ACE-011 protocols describe pregnancy prevention
requiring females of child-bearing potential to use highly effective methods of
birth control.  In addition, since it is unknown if ACE-011 is found in breast milk,
breast feeding is prohibited in all protocols.

Fertility

In male rats, sperm granulomas and testicular degeneration were observed
histologically.  In addition, sperm analysis revealed a reduction in sperm counts
and motility as well as sperm fragmentation in isolated animals (2/10 males) at
doses of 30 mg/kg IV.  Sperm fragmentation was also noted in 2/5 males
administered 10 mg/kg IV at the end of the recovery period.  Overall, there was
some evidence of recovery (motility similar to controls) at the end of the 4-week
recovery period.  There was no evidence of a treatment-related impact on
reproductive organs (testes, ovary, uterus) of monkeys in the toxicity studies;
however, the monkeys on these studies, were too immature to fully assess the
potential impact on reproductive organs.  The NOAEL for reproductive effects
(testicular or ovarian) was 1 mg/kg IV.  Serum exposure (AUC28d) in rats at the
NOAEL was estimated to be ~ 8,000 µg·hr/mL based on the single-dose IV
pharmacokinetic study in rats (Report TR148), ~ 2-fold greater than the serum
exposure observed in humans at the maximum proposed dose of 60 mg every 6
weeks (estimated AUC28d ~ 4548 μg·hr/mL).

In summary, in view of the potential risks ACE-011 treatment has on fertility,
ACE-011 is targeted toward patient groups for whom the potential benefits
outweigh the perceived risks.
Because of the potential risks ACE-011 treatment has on fertility, ACE-011 was first studied in 
healthy postmenopausal women in two completed phase 1 clinical trials.  In addition, due to the 
Page 37 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
23
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
potential for effects on hormones in the pituitary, levels of growth hormone, ACTH, and thyroid 
stimulating hormone (TSH) were monitored closely in the phase 1 studies.  
Completed studies in humans carried out in postmenopausal females showed a dose-dependent 
decrease in circulating levels of FSH, with mean levels in the multidose study in the two higher 
dose groups remaining below baseline at study end.  FSH will continue to be evaluated in 
ongoing studies.  No abnormal effects of ACE-011 on growth hormone, ACTH, TSH or kidney 
toxicities were observed.  
Based on the safety data from the two completed phase 1 studies, single doses of ACE-011 up to 
3.0 mg/kg IV and multiple doses of ACE-011 up to 0.3 mg SC were generally well tolerated in 
healthy postmenopausal women.  Consistent with observations from nonclinical safety studies, 
many of the observed pharmacodynamic effects in the phase 1 clinical studies could be attributed 
to the expected biologic activity of activin inhibition, i.e., dose-dependent decrease in circulating 
levels of FSH, and transient, reversible effects on RBC parameters.  In Study A011-02, one 
subject experienced persistent, progressive hypertension and headaches approximately 1 week 
following her second dose of 1.0 mg/kg ACE-011 SC that were attributed to a rapid and 
significant rise in Hgb levels.  The hypertension was reported as an SAE.  
In regards to the above safety concerns, appropriate vitals, hematologic, clinical chemistry and 
endocrine testing will be closely monitored in this clinical study.  There may be an effect of 
delayed wound healing; thus subjects with major surgeries within 30 days prior to study 
initiation will be excluded.  As with all biologics there is the potential for anti-drug antibodies 
that can be associated with increased drug clearance and hypersensitivity reactions.  Although no 
current evidence of neutralizing anti-drug antibodies formation was seen in two completed phase 
1 clinical trials, anti-drug antibody formation will be monitored in this clinical study.  
Please refer to the Investigator Brochure for further detailed information on the available 
pharmacology, toxicology, drug metabolism, clinical studies and AE profile of ACE-011.
Page 38 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
24
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
2.
STUDY OBJECTIVES
2.1.
Primary Objective

To measure red blood cell mass change and plasma volume following one dose of 
ACE-011 in cancer subjects with solid tumors
2.2.
Secondary Objectives

To measure plasma volume change following one dose of ACE-011 in cancer 
subjects with solid tumors

To evaluate the potential change in hematopoietic parameters

To evaluate the safety and tolerability of ACE-011
2.3.
Exploratory Objectives

To evaluate treatment-related biomarkers

To evaluate the change in precursors in the bone marrow and blood

To measure gene expression levels in hematopoiesis

To evaluate pharmacokinetics of ACE-011
Data from exploratory objectives may not be included in the Clinical Study Report.
Page 39 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
25
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
3.
STUDY ENDPOINTS
3.1.
Primary Endpoint(s)

Red blood cell mass
3.2.
Secondary Endpoint(s)

Plasma volume

Absolute reticulocyte increase

Change in erythropoietin levels with any increase in hemoglobin subtypes determined 
by electrophoresis

Changes in hemoglobin subtypes determined by hemoglobin electrophoresis

Safety (type, frequency, and severity [according to the currently active minor version 
of National Cancer Institute (NCI) Common Terminology for Adverse Events 
(CTCAE) version 4.0] of adverse events, and relationship to ACE-011)
3.3.
Exploratory Endpoint(s)

Change in bone mineral density (BMD)

Changes in serum bone specific alkaline phosphatase (BSAP) and urinary N-
telopeptide (uNTX) and other soluble or cellular biomarkers that may be altered in 
response to ACE-011

Measurement of erythroid pre-cursors in bone marrow and blood using flow 
cytometry

Measurement of gene expression profiles in mononuclear cells isolated from bone 
marrow

Concentrations of ACE-011 in serum
Page 40 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
26
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
4.
OVERALL STUDY DESIGN
4.1.
Study Design
This is a phase 2, open-label, pharmacodynamic study to measure the change in red blood cell 
mass and plasma volume following one 35 mg SC dose of ACE-011 in subjects with solid 
tumors.  No fewer than 10 subjects will be enrolled into the study.
ACE-011 (35 mg SC dose) will be administered to each subject who will be their own internal 
control with a pre-ACE-011 and post-ACE-011 RBC/PV test.  The measures for analysis of the 
RBC and hematopoietic effect are lab-related and nuclear scan-related and therefore not subject 
to biased results.  Subjects may receive up to a total of three doses of ACE-011 during the study
(Study Day 1, 43, and 85).
4.1.1.
ACE-011 Dose Modification Rules
Subjects should have Hgb and blood pressure measured prior to each dose of investigational 
product (IP).  The Investigator must adhere to the following hemoglobin (Hgb) and blood 
pressure-based dose modification rules (see Table 2) for ACE-011 for the subjects’ second dose 
of ACE-011 and beyond.
Page 41 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
27
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Table 2:
Dose Reduction and Modification Guidelines
NCI Toxicity 
Grade
Event
Action
Hypertension:
SBP 150 mmHg
DBP 100 mmHg

Dose delay 1

Hold dose until hypertension resolves < SBP 150 
mmHg and < DBP 100 mmHg

Resume dosing 7 days or later after previously 
scheduled treatment visit
Grade 3
Other non-hematological
ACE-011 related AEs

Dose delay1

Hold dose until resolves < Grade 2

Resume dosing 7 days or later after previously
scheduled treatment visit
For Hemoglobin < 11 g/dL
Hgb < 2 g/dL increase 
within a dosing period or 
a 2 g/dL increase not 
sustained for a 28-day 
period since last dosing 
day

Continue dosing
Hgb > 2 g/dL increase 
sustained for a 28-day
period from last dose

Re-evaluate Hgb & BP prior to resuming treatment

Resume dosing – one level dose reduction (See 
Table 3)
Hgb > 3 g/dL increase 
sustained for a 28-day 
period from last dose

Re-evaluate Hgb & BP prior to resuming treatment

Resume dosing – two level dose reduction (See 
Table 3)
For Hemoglobin 11 g/dL
Hgb < 2 g/dL increase 
within a dosing period or 
a 2 g/dL increase not 
sustained for a 28-day 
period since last dosing 
day

Dose delay1 until Hgb < 11 g/dL and hypertension
< SBP 150 mmHg and < DBP 100 mmHg.

Dosing can commence 7 days after the originally 
planned ACE-011 dose that was delayed

Subsequent ACE-011 dosing will resume 42 days 
following this revised treatment dose date
Hgb > 2 g/dL increase 
sustained for a 28-day 
period from last dose

Dose delay1

Hold dose for one treatment visit

Re-evaluate Hgb & BP prior to resuming treatment

If Hgb < 11 g/dL and hypertension < SBP 150 mmHg 
and < DBP 100 mmHg at the next scheduled visit, 
resume dosing – one level dose reduction (See Table 3)
Page 42 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
28
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Table 2:
Dose Reduction and Modification Guidelines (Continued)
NCI Toxicity 
Grade
Event
Action
Hgb > 3 g/dL increase 
sustained for a 28-day 
period from last dose

Dose delay1

Hold dose for one treatment visit

Re-evaluate Hgb & BP prior to resuming treatment

If Hgb < 11 g/dL and hypertension < SBP 150 mmHg 
and < DBP 100 mmHg at the next scheduled visit, 
resume dosing – two level dose reduction (See Table 3)
For Hemoglobin > 15 g/dL
Hgb is > 15 g/dL, 
sustained for a 7-day 
period from last dose

Discontinue treatment (See Section 8.2.3)
1 A delayed ACE-011 dose is defined as a dose not administered > 3 days from the planned dosing date due to Hgb 
> 11 g/dL, hypertension > SBP 150 mmHg and > DBP 100 mmHg and/or ACE-011 related toxicity.
When required, per dose modification rules above, ACE-011 dose(s) during the Treatment 
Period should be reduced as follows (See Table 3):
Table 3:
ACE-011 Dose Reduction Levels
ACE-011 Starting Dose
35.0 mg
Dose Level -1
30.0 mg
Dose Level -2
26.0 mg
If the subject cannot tolerate Dose Level -2, the subject should be discontinued from the study.
Dosing visits are on Day 1 and repeated every 42 days, for up to three doses.  Blood pressure and 
Hgb values must be evaluated prior to dosing at each dosing day for consideration in 
administration of ACE-011.  
The dose level for the initial dose reduction will be maintained unless subsequent dose 
reductions need to be administered upon evaluation of the dose modification rules listed above.  
Dose escalations are not permitted at any time during the study.
Page 43 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
29
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Figure 1:
Study Design
SCREENING
     PROTOCOL TREATMENT
    FOLLOW-UP
  
E
N
R
O
L
L
M
E
N
T
Subjects 
who meet 
eligibility 
criteria 
and 
provide 
signed 
informed 
consent
Treatment 
Period:
Day 1 to Day 126
ACE-011
35 mg SC dose
on study Day 1 
every 42 days, up 
to 3 doses
(N=10 subjects)
Follow-Up Period:
Day 155 to Day 210 
after study Day 1 
dose
Study 
Discontinuation:
Day 211 after
study Day 1 dose
Treatment 
Discontinuation:
Day 127 after
study Day 1 dose
Page 44 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
30
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
4.2.
Study Design Rationale
The A011-01, A011-02, and A011-04 studies have shown that dosing with ACE-011 resulted in 
the increase in hematopoietic parameters, beginning rapidly and sooner than would be expected 
from a stimulation of the erythropoietic effect by an ESA.  This fact, as well as the fairly rapid 
and persistent elevation in the relative Hgb, HCT, and RBC counts of the majority of subjects
from each dose of ACE-011, suggests an entirely novel mechanism of RBC production.  In order 
to establish that RBCs are produced following ACE-011 therapy, the Sponsor has received 
expert advice and regulatory authority comment that an RBC mass and plasma volume study 
should be completed, prior to formulating a registration strategy for this agent.  The secondary 
and exploratory endpoints are designed to elucidate the mechanism of the red blood cell effect in 
cancer patients with solid tumor malignancies.
4.2.1.
Fixed Dose
ACE-011 dose will be fixed at the indicated levels regardless of the subject’s body weight.  The 
fixed dosing approach is supported by an exploratory analysis of the relationship between body 
weight and ACE-011 PK in the previous studies (A011-01, A011-02, and A011-04).  In healthy 
postmenopausal women (Studies A011-01 and A011-02), body weight was estimated to explain 
less than 2.5% of intersubject variability for the two PK parameters dictating ACE-011 exposure, 
clearance and central volume of distribution, compared to an overall intersubject variability of 
17.4%-25.5% for the two parameters.  In MM subjects (Study A011-04), body weight had no 
apparent effect on ACE-011 exposure.  Because the Hgb response is dependent on ACE-011 
exposure and because body weight is not a major source for the intersubject variability of ACE-
011 exposure, a fixed dosing approach is considered to be appropriate for the current study.
The 35 mg starting dose is equivalent to the 0.5 mg/kg dose for a 70 kg subject. This dose was 
chosen primarily based on the safety and efficacy data observed in MM subjects (Study A011-
04). In MM subjects who received ACE-011 at 0.5 mg/kg every 4 weeks for up to four doses, 
ACE-011 had an acceptable safety profile and caused significant Hgb response.
4.2.2.
Dosing Schedule
The dosing schedule of once every 42 days (6 weeks) is proposed for the current study.  This 
dosing schedule was chosen based on the rapid and prolonged Hgb response to ACE-011
observed in previous clinical studies.  The Hgb-increasing effect of ACE-011 was usually 
evident approximately 1 week after a SC dose and remained detectable through 6-8 weeks.
4.3.
Study Duration 
To evaluate sequence and study timelines, please see the Table of Events (see Table 4).  No 
fewer than 10 subjects will be enrolled into the study.  Each subject will be on the study for 
approximately 8 months (including the Screening Period, the Treatment Period, and the Follow-
Up Period).
The Treatment Period will be up to approximately four months (up to 3 doses of ACE-011 to be 
administered every 42 days through study Day 126) with a post-treatment Follow-Up Period of 
three months from the subjects’ last dose of ACE-011 (through study Day 210).  Subjects who 
Page 45 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
31
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
discontinue from the Treatment Period early will still continue to the Follow-Up Period for three
months (84 days) from their last dose of ACE-011.
Page 46 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
32
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
5.
TABLE OF EVENTS
Table 4:
ACE-011 RBC/PV Table of Events
Assessments
Screening 
Period
Treatment (Tx) Period
Tx
DC
Follow-Up 
Period
Study
DC
D-28
to D-1
D1 a
(±1d)
D3
(±1d)
D7
(±1d)
D14
(±2d)
D21
(±2d)
D29
(±2d)
D43a
(±3d)
D57
(±3d)
D71
(±3d)
D85a
(±3d)
D99
(±3d)
D113
(±3d)
D127
(±3d)
D155
(±7d)
D183
(±7d)
D211
(±7d)
Informed Consent
X
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Inclusion / Exclusion Criteria
X
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Complete Medical History
X
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Prior Therapies b
X
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
ECOG Performance Status
X
X
-
-
-
X
X
X
X
X
X
X
X
X
X
X
X
Vital Signs / Blood Pressure c
X
X
Xd
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Height
X
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Weight
X
X
-
-
-
-
X
X
-
-
X
-
X
X
X
X
X
12-Lead Electrocardiogram
X
-
-
-
X
-
X
X
-
-
X
-
-
X
-
-
X
Pregnancy Testing e
X
(within 3 
days prior 
to Day 1)
-
-
-
-
-
-
X
-
-
X
-
-
X
X
X
X
Hematology f
X
X
Xd
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Chemistry g
X
-
-
-
X
-
X
X
-
-
X
-
-
X
-
-
X
BUN and Creatinine
-
-
-
Xh
-
-
-
-
-
-
-
-
-
-
-
-
-
Absolute Reticulocyte Count
X
X
Xd
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum Iron, TIBC, Transferrin 
and Serum Ferritin
X
-
-
-
-
-
-
-
X
-
-
-
-
X
-
-
X
Page 47 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
33
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Table 4:
ACE-011 RBC/PV Table of Events (Continued)
Assessments
Screening 
Period
Treatment (Tx) Period
Tx
DC
Follow-Up 
Period
Study 
DC
D-28
to D-1
D1 a
(±1d)
D3
(±1d)
D7
(±1d)
D14
(±2d)
D21
(±2d)
D29
(±2d)
D43a
(±3d)
D57
(±3d)
D71
(±3d)
D85a
(±3d)
D99
(±3d)
D113
(±3d)
D127
(±3d)
D155
(±7d)
D183
(±7d)
D211
(±7d)
Serum Erythropoietin
-
X
-
-
X
-
X
X
-
-
X
-
-
X
X
X
X
Hemoglobin Electrophoresis
-
X
-
X
X
-
X
-
-
-
-
-
-
-
-
-
-
B12 and Serum Folate
X
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FSH and LH – Males / Females
X
X
-
-
X
-
X
X
X
-
X
X
-
X
-
-
X
TSH
X
X
-
-
-
-
-
X
-
-
X
-
-
X
-
-
X
RBC Mass / Plasma Volume
X
-
-
-
X
(at one 
additional time 
point; must be 
between D14 
and D28)
-
-
-
-
-
-
-
-
-
-
-
Bone Marrow Aspirate (BMA) 
(optional for consented subjects)
X
-
-
-
-
X
-
-
-
-
-
-
-
-
-
-
-
Bone Mineral Density DXA Scan i
X
-
-
-
-
-
-
-
X
-
-
-
X
-
X
-
-
Biomarkers in blood and urine j
X
-
-
X
-
-
X
-
X
-
-
-
X
X
X
-
X
Pharmacokinetics k
-
X
Xd
X
X
X
X
X
X
-
X
X
-
X
-
-
X
Anti-ACE-011 antibody test l
-
X
-
-
-
-
-
X
-
-
X
-
-
-
-
-
X
Adverse Events
X
X
Xd
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant Medications
X
X
Xd
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Concomitant Procedures
X
X
Xd
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Administer ACE-011
-
X
-
-
-
-
-
X
-
-
X
-
-
-
-
-
-
a. All D1, D43, and D85 assessments are to be done prior to ACE-011 administration.
b. All prior cancer and medical diagnosis, radiotherapy, surgeries, and chemotherapies and approximate dates of therapies must be recorded.  
c. Vital signs (including heart rate, seated blood pressure, and temperature) will be measured at Screening, at all subsequent visits during the Treatment and 
Follow-Up Periods, and at Study DC (Discontinuation) visit.  Investigators are to report any clinically significant abnormal findings as adverse events.
d. D3 visit is optional; however, these tests are strongly suggested for all subjects on study.
Page 48 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
34
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
e. Females of childbearing potential (FCBP):  A female of childbearing potential is a sexually mature woman who has not undergone a hysterectomy or who has 
not been postmenopausal for at least 24 consecutive months (i.e. who has had menses at some time in the preceding 24 months).  A medically supervised 
pregnancy test (which must be negative) with a minimum sensitivity of 25 mIU/mL must be performed no more than 3 days from the start of ACE-011 
administration (D1).  Furthermore, subjects must be on effective contraception for at least 28 days prior to D1 and throughout the remainder of the study 
including the Follow-up Period.  For all additional subsequent doses, a pregnancy test must be performed within 3 days prior to administrations of ACE-011 as 
indicated above.  Subjects must agree to use highly effective methods of birth control during study participation and for at least 112 days following the last dose 
of ACE-011.  Subjects must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of ACE-011.  
Pregnancy tests will be performed according to the above schedule during study participation.  For FCBP, a final pregnancy test must be performed at least 112 
days following the last dose of ACE-011.
f. Hematology laboratory evaluations (RBC count, hemoglobin, hematocrit, WBC count and differential, ANC, and platelet count) will be collected at Screening, 
at subsequent visits during the Treatment and Follow-Up Periods, and at Study DC visit, as referenced in the schedule above.  Any laboratory evaluations may 
be repeated more frequently if clinically indicated.
g. Serum chemistry laboratory evaluations (sodium, potassium, chloride, CO2 (bicarbonate), calcium, magnesium, phosphorus, BUN, creatinine, glucose, 
albumin, total protein, alkaline phosphatase, bilirubin [total and direct], AST/SGOT, ALT/SGPT, LDH and uric acid) will be collected at Screening, and at 
days referenced in the schedule above.  Any laboratory evaluations may be repeated more frequently if clinically indicated.
h. At D7, only BUN and creatinine to confirm no plasma volume contraction.
i. Optional dual energy X-ray absorptiometry (DXA) scan to evaluate overall bone health in subjects with known bone metastases.
j. BSAP, uNTX, and other ACE-011 soluble and cellular biomarkers.  Both blood and urine samples will be collected on the days indicated above.  The urine 
sample should not be from the first morning void.
k. PK sample will be collected at each study visit indicated above (a total of 12 visits, one sample per visit), including D1 (prior to ACE-011 administration), D3
(optional), D7, D14, D21, D29, D43 (prior to ACE-011 administration), D57, D85 (prior to ACE-011 administration), D99, D127, and D211.
l. Samples for anti-ACE-011 antibody testing should be collected prior to ACE-011 administration on D1, D43, and D85.  If a subject has a positive anti-
ACE-011 antibody result at the Study DC visit, the subject may be asked to return to the clinical site for additional monthly follow-up, for up to 12 months 
after their last dose of ACE-011 for a repeat anti-ACE-011 antibody test.
Page 49 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
35
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
6.
PROCEDURES
Screening Period (Day -28 to Day -1)
Potentially protocol-eligible subjects will enter the Screening Period and be evaluated for the 
inclusion and exclusion criteria for the Treatment Period of this study.
The Screening Period will not last more than 28 days (4 weeks).  The assessments and 
procedures that will be performed during this period are outlined in the Table of Events (see 
Table 4) and include but are not limited to:

Informed consent

Assessment of inclusion / exclusion criteria

Complete medical history

ECOG performance status

Vital signs including height, weight, heart rate, seated systolic and diastolic blood 
pressure, and temperature

12-lead electrocardiogram (ECG)

Medically supervised pregnancy test (which must be negative) with a minimum 
sensitivity of 25 mIU/mL for FCBP to be assessed within 3 days of Day 1 (pre-dose)

Serum chemistry, hematology, absolute reticulocyte count

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Vitamin B12 and serum folate levels

Follicle stimulating hormone (FSH) and luteinizing hormone (LH) – both males and 
females

Thyroid stimulating hormone (TSH)

Red blood cell mass / plasma volume

Bone marrow aspirate (optional)

Bone imaging DXA scan (only for subjects with known bone metastases)

Biomarkers (blood and urine)

Evaluation of adverse events

Documentation of concomitant medications / procedures
Page 50 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
36
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Treatment Period (Day 1 to Day 126)
Results from screening evaluations must be reviewed prior to enrollment to confirm subject
eligibility.  Subjects satisfying all inclusion and exclusion criteria will be enrolled into the 
Treatment Period.  A subject will be considered enrolled once a multi-digit subject identification 
number has been manually assigned by the site.  After assignment of the subject identification 
number and the inclusion/exclusion criteria have been met, subjects will receive the first 
subcutaneous 35 mg dose of ACE-011 on study Day 1.
The Treatment Period will not last more than 126 days (18 weeks).  The assessments and 
procedures that will be performed during this period are outlined in the Table of Events (see 
Table 4) and include but are not limited to:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

12-lead electrocardiogram (ECG)

Medically supervised pregnancy test with a minimum sensitivity of 25 mIU/mL for 
FCBP

Serum chemistry, hematology, absolute reticulocyte count

BUN and creatinine (Day 7 only)

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Serum erythropoietin

Hemoglobin electrophoresis

Follicle stimulating hormone (FSH) and luteinizing hormone (LH) – both males and 
females

Thyroid stimulating hormone (TSH)

Red blood cell mass / plasma volume (post-dose test must be performed between 
study Day 14 and Day 28)

Bone marrow aspirate at Day 21 (optional)

Bone imaging DXA scan (only for subjects with known bone metastases)

Biomarkers (blood and urine)

Pharmacokinetics

Anti-ACE-011 antibody test (pre-dose on Day 1, Day 43, and Day 85) 

Administration of ACE-011 (Day 1, Day 43, and Day 85)

Evaluation of adverse events

Documentation of concomitant medications / procedures
Page 51 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
37
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Subjects discontinued after Day 28 of the Treatment Period, having completed their second RBC 
mass and PV test, will not need to be replaced unless their hemoglobin did not increase after the 
ACE-011 dose.  Subjects discontinued for any cause prior to Day 28 or before their second 
RBC/PV test is completed will need to be replaced.
Treatment Discontinuation (Day 127)
Subjects who complete the Treatment Period or discontinue from the Treatment Period early will 
complete the Treatment Discontinuation Visit prior to entering the Follow-Up Period.  The 
assessments and procedures that will be performed during this period are outlined in the Table of 
Events (see Table 4) and include but are not limited to:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

12-lead electrocardiogram (ECG)

Medically supervised pregnancy test with a minimum sensitivity of 25 mIU/mL for 
FCBP

Serum chemistry, hematology, absolute reticulocyte count

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Serum erythropoietin

Follicle stimulating hormone (FSH) and luteinizing hormone (LH) – both males and 
females

Thyroid stimulating hormone (TSH)

Biomarkers (blood and urine)

Pharmacokinetics

Evaluation of adverse events

Documentation of concomitant medications / procedures
Follow-Up Period (Day 155 to Day 210)
Following completion of the Treatment Period, all subjects will be followed for an additional 84 
days (12 weeks).  The assessments and procedures that will be performed during this period are 
outlined in the Table of Events (see Table 4) and include but are not limited to:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

Medically supervised pregnancy test which must be negative with a minimum 
sensitivity of 25 mIU/mL for FCBP

Serum chemistry, hematology, absolute reticulocyte count

Serum erythropoietin
Page 52 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
38
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012

Bone imaging DXA scan (only for subjects with known bone metastases)

Biomarkers (blood and urine)

Evaluation of adverse events

Documentation of concomitant medications / procedures
Additional Procedures

Exploratory Bone Mineral Density
A dual energy X-ray absorptiometry (DXA) scan will be performed during the 
Screening Period as well as during the Treatment and Follow-Up Periods (see 
Table 4) to evaluate overall bone health in subjects with known bone metastases.

Exploratory Biomarkers
Anabolic bone biomarkers in blood and urine will be evaluated at 8 visits (see 
Table 4).  These biomarkers will include bone specific alkaline phosphatase (BSAP) 
and urinary N-telopeptide (uNTX).  Other ACE-011 soluble and cellular biomarkers 
may also be evaluated in samples collected from all subjects during the Screening, 
Treatment, and Follow-Up Periods.

Exploratory Pharmacokinetics (PK)
Additional blood samples for PK will be taken at up to 12 visits during the Treatment 
Period (see Table 4) (optional at Day 3; however, these tests are strongly suggested 
for all subjects on study) for evaluation of serum concentrations of ACE-011 and for 
exploratory analysis.  Collection, handling, and shipping procedures for blood 
samples are provided in the study reference guide.
Study Discontinuation Visit (Day 211)
Study Discontinuation is the final scheduled visit for this study and should be performed for all 
enrolled subjects.  If a subject discontinues from the study early, the Study Discontinuation Visit 
procedures should be followed.  The assessments and procedures that will be performed during 
the Study Discontinuation Visit are outlined in the Table of Events (see Table 4) and include but 
are not limited to:

ECOG performance status

Vital signs including weight, heart rate, seated systolic and diastolic blood pressure, 
and temperature

12-lead electrocardiogram (ECG)

Medically supervised pregnancy test with a minimum sensitivity of 25 mIU/mL for 
females of childbearing potential (FCBP)

Serum chemistry, hematology, absolute reticulocyte count

Serum iron, total iron binding capacity (TIBC), transferrin and serum ferritin

Serum erythropoietin
Page 53 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
39
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012

Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) – both males 
and females

Thyroid Stimulating Hormone (TSH)

Biomarkers (blood and urine)

Pharmacokinetics

Anti-ACE-011 antibody test

Evaluation of adverse events

Documentation of concomitant medications / procedures
The reason for discontinuation should be recorded in the CRF and in the source documents.
Page 54 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
40
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
7.
STUDY POPULATION
7.1.
Number of Subjects and Sites
This pharmacodynamic study will enroll no fewer than 10 subjects with at least 4 males or
females.
7.2.
Inclusion Criteria
1. Men and women > 18 years of age.
2. Histologically confirmed diagnosis of a solid tumor malignancy documented by cytology 
or biopsy.
3. Presence of metastatic disease.
4. Hemoglobin value between ≥ 8.0 to < 11.0 g/dL (≥ 80 to < 110 g/L).
5. ≥ 28 days must have elapsed (prior to pre-dose RBC mass / PV test) since previous 
treatment with erythropoiesis-stimulating agent (including concurrent treatment with IV 
iron).
6. ≥ 28 days must have elapsed (prior to Day 1) since the last RBC blood transfusion and 
receipt of ≤ 2 units of blood in the past 56 days (prior to Day 1).
7. ECOG Performance status of 0 – 1 (Appendix A).
8. Adequate renal (creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 40 mL/min) and hepatic 
function (bilirubin < 1.5 x ULN; AST/ALT < 2.5 x ULN).
9. Females of childbearing potential participating in the study are to use highly effective 
methods of birth control for at least 28 days before starting the study, during study 
participation and for 112 days following the last dose of ACE-011.
Some highly effective methods of birth control include:

Oral contraceptives, intrauterine device, tubal ligation or a partner with vasectomy
OR

Two forms of barrier method birth control, e.g., a latex condom PLUS a diaphragm 
with spermicide OR a latex condom PLUS a contraceptive sponge with spermicide.  
If a non-latex condom is used, it cannot be made out of natural (animal) membrane.
Females of childbearing potential must have a medically supervised pregnancy test 
(which must be negative) within 3 days prior to the start of ACE-011 administration on 
Day 1. Subjects must be counseled concerning measures to be used to prevent pregnancy 
and potential toxicities prior to the first dose of ACE-011. A female of childbearing 
potential is a sexually mature woman who has not undergone a hysterectomy or bilateral 
oophorectomy; or who has not been postmenopausal for at least 24 consecutive months 
(i.e. who has had menses at some time in the preceding 24 months).
Page 55 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
41
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
10. Males must agree to use a latex condom or non-latex condom NOT made of natural 
(animal) membrane during any sexual contact with females of childbearing potential or a 
pregnant female while participating in the study and for 112 days following the last dose 
of ACE-011, even if he has undergone a successful vasectomy.
11. Life expectancy of ≥ 6 months.
12. Is willing to adhere to the study visit schedule, understand and comply with all protocol 
requirements.
13. Understand and sign a written informed consent.
7.3.
Exclusion Criteria
1. At the time of screening, subjects who have any grade > 3 toxicity (according to the 
currently active minor version of NCI CTCAE v4.0 [Appendix B], except for the 
following disease related toxicities:  hematological events- anemia, thrombocytopenia or 
neutropenia or non hematological events- nausea, vomiting, fatigue, or muscle or 
bone/joint pain).
2. Prior radiation therapy to > 20% of the whole skeleton.  Use of palliative radiation if the 
area being treated is <15% of body surface area with no pelvic radiation or no more than 
10% of the bone marrow reserve is radiated is permitted during patient participation in 
the study, at the discretion of the investigator.
3. Clinically significant pulmonary, endocrine, neurologic, gastrointestinal, hepatic or 
genitourinary disease unrelated to underlying hematologic disorder.
4. Patients with heart failure as classified by the New York Heart Association (NYHA) 
classification of 3 or higher (Appendix C).
5. History of thrombosis, deep vein thrombosis (DVT), pulmonary emboli, or embolic 
stroke.
6. Untreated CNS metastases (exception:  CNS metastases treated with whole brain 
radiotherapy > 6 months prior to enrollment at study Day 1).
7. Diagnosis of a myeloid malignancy or known history of myelodysplasia.
8. History of second malignancy within 3 years (except excised and cured basal cell 
carcinoma, squamous cell carcinoma of the skin or cervical carcinoma in situ).
9. Patients with a recent history (within 14 days of Day 1) of administration of systemic (IV 
or oral) antibiotics.  Patients should be free of infection at least 14 days after the last dose 
of systemic antibiotic treatment (prior to Day 1).
10. Uncontrolled hypertension.  If hypertension is considered clinically stable, systolic blood 
pressure (BP) must be < 150 mmHg and diastolic BP must be < 100 mmHg.
11. Known history of hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg and 
HB core Ab), or human immunodeficiency virus (HIV) antibody.
12. Deficiency in iron (serum ferritin < 100 ng/mL [< 224.7 pmol/L]), vitamin B12, or folate.
Page 56 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
42
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
13. History of anemia as a result of inherited hemoglobinopathy such as sickle cell anemia or 
thalassemia.
14. History of autoimmune or hereditary hemolysis or gastrointestinal bleeding.
15. Received treatment with another investigational drug or device within 28 days prior to 
Day 1, or if the half life of the previous product is known, within 5 times the half life 
prior to dosing, whichever may be longer.
16. Any prior use of ACE-011.
17. Pregnant or lactating females.
18. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant 
proteins or excipients in the investigational product (see Investigator Brochure).
19. History of iodinated dye allergy.
20. Major surgery within 30 days prior to Day 1 (subjects must have completely recovered 
from any previous surgery prior to Day 1).
7.4.
Subject Withdrawal Criteria
Subjects will be informed that they have the right to withdraw from the study at any time for any 
reason without prejudice to their medical care.  
Subjects must be withdrawn from the study for any of the following reasons:  

Subject request

Subject is unwilling or unable to comply with the protocol

ESA administration during the treatment period

Disease progression

Medical reason, such as cancer or unacceptable toxicity, or at the discretion of the 
Investigator and/or the Medical Monitor(s)
The reasons for withdrawal must be recorded in the subject’s case report form (CRF).  The 
Investigator must notify the Medical Monitor immediately when a subject has been discontinued 
/ withdrawn due to an AE (e.g. unacceptable toxicity).  All subjects who are withdrawn from the 
study should complete the tests and evaluations scheduled for Study Discontinuation at the time 
of withdrawal.
Page 57 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
43
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
8.
DESCRIPTION OF STUDY TREATMENTS
8.1.
Description of Investigational Product(s)
Sotatercept (ACE-011) clinical drug product will be provided as a lyophilized powder, Process 
III.  
Process III Clinical Drug Product-Lyophilized Powder:
The clinical drug product consists of ACE-011 in 10 mM citrate buffer, pH 5.8, 8% sucrose, and 
0.02% polysorbate 80. It is supplied as a lyophilized powder in labeled, rubber stoppered, 3-mL 
glass vials. The recommended storage temperature for ACE-011 lyophilized drug product is 2°C 
to 8°C. Prior to administration, the lyophilized drug product is reconstituted with 1 mL water for 
injection (WFI). The reconstituted drug product consists of a 50 mg/mL solution of ACE-011.
The reconstituted ACE-011, in its original container closure system, may be held for up to 6 
hours at 2°C to 8°C.
8.2.
Treatment Administration and Schedule
Each dose of ACE-011 will be administered as a subcutaneous injection at the clinical site by the 
study staff and will be documented in the study source record.  Subcutaneous injections will be 
given in the upper arm or thigh.
8.2.1.
Selection of Dose for the Study
ACE-011 administered as a single dose up to 3.0 mg/kg was previously demonstrated to be safe 
and to have durable effects on markers of bone formation and resorption as well as red blood 
cells following a single IV administration.  A dose-limiting pharmacodynamic effect of ACE-
011 with increases in hemoglobin, hematocrit and RBCs was established in healthy post-
menopausal women at the 1.0 mg/kg dose level following multiple SC administration.  This 
study will further delineate the hematopoietic profile of ACE-011 in cancer subjects.
8.2.2.
Selection and Timing of Dosing for Each Patient
Subjects will be enrolled and receive their first dose of ACE-011 on study Day 1.  Up to two 
additional doses of ACE-011 will be administered every 42 days during the Treatment Period 
(Day 43 and Day 85).  After completion of the Treatment Period, subjects will return to the site 
for three additional monthly visits (Day 127, Day 155, and Day 183) during the Follow-Up 
Period, and a Study Discontinuation Visit (Day 211).
Subjects will be discontinued from study participation for reasons listed in Section 12 of the 
protocol, for unacceptable toxicity, or for disease progression that requires the initiation of 
another treatment during the first 28 days of the Treatment Period.
Page 58 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
44
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
8.2.3.
Treatment / Study Discontinuation
Refer to Section 12 Discontinuations.
8.3.
Method of Treatment Assignment
All subjects who qualify for enrollment into the study will enter the Treatment Period and 
receive their first subcutaneous 35 mg dose of ACE-011 on study Day 1.  A unique subject 
identification number will be manually assigned by the site staff to each subject entering the 
Treatment Period.
Subjects discontinued after Day 28 of the Treatment Period, having completed their second RBC 
mass and PV test, will not need to be replaced unless their hemoglobin did not increase after the 
ACE-011 dose.  Subjects discontinued for any cause prior to Day 28 or before their second 
RBC/PV test is completed will need to be replaced.
8.4.
Packaging and Labeling
The label(s) for IP will include Sponsor name, address and telephone number, the protocol 
number, IP name, dosage form and strength (where applicable), amount of IP per container, lot 
number, expiry date (where applicable), medication identification/kit number (if applicable), 
dosing instructions, storage conditions, and required caution statements and/or regulatory 
statements as applicable.  Additional information may be included on the label as applicable per 
local regulations.
8.5.
Investigational Product Accountability and Disposal
Accountability for ACE-011 is the responsibility of the Investigator.  Investigational clinical 
supplies must be received by a designated person at the clinical site and kept in a secure and 
temperature-controlled location.  The investigational site must maintain accurate records 
demonstrating dates and amounts of ACE-011 received, to whom it was administered (subject-
by-subject accounting), and accounts of any ACE-011 accidentally or deliberately destroyed or 
returned.  Unless otherwise notified, all vials of ACE-011, both used and unused, must be saved 
for drug accountability.  The used vials may be discarded, per the institution’s standard practice, 
after drug accountability has been completed by the monitor.  The Investigator must return all 
unused vials of ACE-011 to the Sponsor at the end of the study, or the ACE-011 may be 
destroyed at the clinical site with the permission of the Sponsor.  For either scenario, the 
outcome must be documented on the drug accountability log.  The Sponsor will provide direction 
for the outcome of all unused vials.
Celgene will instruct the Investigator on the return, disposal and/or destruction of IP.
8.6.
Investigational Product Compliance
Accurate recording of all IP administration will be made in the appropriate section of the 
subject’s CRF and source documents.
The Investigator or designee is responsible for accounting for all IP that is administered during 
the course of the study.
Page 59 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
45
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
9.
CONCOMITANT MEDICATIONS AND PROCEDURES
9.1.
Permitted Concomitant Medications and Procedures
9.1.1.
General concomitant medication usage
During screening, and during the study, subjects may take only stable doses of medications for 
chronic conditions that are not specifically excluded by the protocol (see Sections 7.2 Inclusion 
Criteria and 7.3 Exclusion Criteria).  The Medical Monitor should be consulted by the 
Investigator if there are any concerns about what constitutes a stable dose or what is a chronic 
condition.  Concomitant medications will be recorded on the subject’s CRF throughout the 
course of the study.
9.1.2.
Concomitant medication for anemia
Concurrent therapy with a new prescription medication related to treatment of anemia during the 
course of the study must first be discussed with the Medical Monitor prior to administration, 
unless appropriate medical care necessitates that medication should begin before the Medical 
Monitor can be consulted.
9.1.2.1.
Iron supplementation
Iron supplementation within 7 days of Day 1 (besides an oral general multivitamin with iron) 
will not be allowed.  If a patient becomes iron deficient during study treatment (ferritin < 100 
ng/mL [< 224.7 pmol/L] or transferrin < 20%), treatment with iron supplementation is at the 
discretion of the investigator.
9.1.2.2.
RBC transfusions
Concurrent treatment for chemotherapy-induced anemia with blood transfusions is recommended 
when hemoglobin value is < 8 g/dL or at the discretion of the Investigator if the hemoglobin 
value is above 8 g/dL and associated with anemia symptoms such as hemodynamic or pulmonary 
compromise requiring treatment.  If a transfusion is given to a subject during the Screening 
Period, ACE-011 should be administered no sooner than 28 days from the date of the 
transfusion.  On the day of ACE-011 administration (study Day 1, Day 43, and Day 85), the 
blood pressure and other vital signs will also be assessed to ensure that the subject is still eligible 
for participation in the study.
9.2.
Prohibited Concomitant Medications and Procedures
Erythropoiesis-stimulating agents (ESAs) cannot be administered during the time between the 
pre-dose RBC / PV test and the post-dose RBC / PV test.  Twenty-one days after the second dose 
of ACE-011 during the Treatment Period, if there is no hemoglobin response (< 1 g/dL rise in 
Hgb) and the use of ESAs is indicated, the subject should be considered a treatment failure and 
discontinued from the study.  If treatment with ESAs is required in the opinion of the 
Investigator, the ESA label instructions are to be followed.
Page 60 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
46
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Intravenous (IV) iron replacement therapy for iron deficiency anemia is not allowed during the 
study.
No concurrent treatments with any other investigational agent are allowed.
9.3.
Required Concomitant Medications and Procedures
Not applicable.
Page 61 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
47
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
10.
STATISTICAL ANALYSES
10.1.
Overview
This is a mechanism of action (MOA) study of ACE-011 as a supportive care agent.  The 
primary objective is to measure the change in red blood cell mass and plasma volume following 
one 35 mg dose of ACE-011 in subjects with solid tumors.  No fewer than ten subjects will be 
enrolled and treated.
10.2.
Study Population Definitions
All analyses will be based on the treated population which is defined as all subjects who take at 
least one dose of study medication.
10.3.
Sample Size and Power Considerations
No fewer than ten subjects will be enrolled.  Assuming standard deviation of 5.5 mL/kg for the 
intra-patient difference in erythrocyte mass (Lim, 1989), this sample size will have at least 90% 
power to detect 5.9 mL/kg pre- and post-ACE-011 therapy at one sided 5% significance level 
based on a paired t-test.
10.4.
Background and Demographic Characteristics
Subjects’ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics, while gender, race and other categorical variables will be provided using frequency 
tabulations.  Medical history data will be summarized using frequency tabulations by system 
organ class and preferred term.
10.5.
Subject Disposition
Subject disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent for both treatment 
and follow-up phases.  A summary of subjects enrolled will be provided.  Protocol deviations 
will be summarized using frequency tabulations.
10.6.
Efficacy Analysis
The effect of ACE-011 will be analyzed based on the treated dataset.  Descriptive statistics will 
be provided for RBC mass and plasma volume pre- and post-ACE-011 therapy.  The pre- and 
post- difference will be compared based on a paired t-test.  In addition, descriptive statistics will 
be provided for secondary endpoints including bone or disease progression, bone mineral 
density, and bone biomarkers.
10.7.
Safety Analysis
Safety analyses will be based on the treated dataset.  ACE-011 exposure will be summarized.  
Adverse events, vital sign measurements, clinical laboratory information, ECG interpretations, 
and concomitant medications will be tabulated and summarized by tumor type.  All toxicities 
Page 62 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
48
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
will be summarized by relative and absolute frequency, severity grade (according to the currently 
active minor version of NCI CTCAE version 4.0), and relationship to treatment.  Serious adverse 
events (SAE) will be listed separately.  Safety information obtained during the Follow-up period 
during each segment will be incorporated into these analyses.  Graphical displays will be 
provided where useful in the interpretation of results.
10.8.
Interim Analysis
An internal Data Monitoring Committee (DMC) will review summaries of the hematopoietic 
endpoints including RBC and PV 29 days post-dose of the last subject being enrolled.
10.9.
Other Topics
Not Applicable.
Page 63 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
49
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
11.
ADVERSE EVENTS
11.1.
Monitoring, Recording and Reporting of Adverse Events
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may 
appear or worsen in a subject during the course of a study.  It may be a new intercurrent illness, a 
worsening concomitant illness, an injury, or any concomitant impairment of the subject’s health, 
including laboratory test values (as specified by the criteria below), regardless of etiology.  Any 
worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-
existing condition) should be considered an AE.  A diagnosis or syndrome should be recorded on 
the AE page of the CRF rather than the individual signs or symptoms of the diagnosis or 
syndrome.
An overdose, accidental or intentional, whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to an IP should be reported as an AE.  If an overdose is 
associated with an AE, the overdose and adverse event should be reported as separate terms.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or other 
appropriate tests and procedures.
All AEs (regardless of relationship to IP) will be recorded by the Investigator from the time the 
subject signs informed consent until at least 42 days after the last dose of IP, up to a maximum of 
112 days post-last dose of IP or until the subject begins a new regimen of chemotherapy.  
Adverse events and serious adverse events (SAEs) will be recorded on the AE page of the CRF 
and in the subject’s source documents.  All SAEs must be reported to Celgene Drug Safety 
within 24 hours of the Investigator’s knowledge of the event by facsimile, or other appropriate 
method, using the SAE Report Form, or approved equivalent form.  After 112 days post-last dose
of IP or once the subject begins a new regimen of chemotherapy, only SAEs assessed as related 
to study treatment are to be reported.
11.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all adverse events as to:  
11.2.1.
Seriousness 
A serious adverse event (SAE) is any AE occurring at any dose that:

Results in death;

Is life-threatening (i.e., in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);

Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);

Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);
Page 64 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
50
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012

Is a congenital anomaly/birth defect;

Constitutes an important medical event.
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospitalizations for:

A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE.  

Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.

The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.

A procedure for protocol/disease-related investigations (e.g., surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.

Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.

A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the CRF.  Hospitalization or 
prolonged hospitalization for a complication remains a reportable SAE.

An elective treatment of a pre-existing condition unrelated to the studied indication.  

Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page of the CRF and the SAE Report Form must be 
completed.
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.
11.2.2.
Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity / intensity of the event.  
The severity of AEs will be graded based upon the subject’s symptoms according to the currently 
active minor version of the National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE, Version 4.0); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 65 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
51
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
AEs that are not defined in the NCI CTCAE should be evaluated for severity according to the 
following scale:
Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be needed; no 
or minimal medical intervention/therapy required
Grade 3 = Severe – marked limitation in activity, some assistance usually required; medical 
intervention/therapy required, hospitalization is possible
Grade 4 = Life threatening – extreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, hospitalization or hospice care probable
Grade 5 = Death – the event results in death
The term “severe” is often used to describe the intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is not the same as “serious” which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subject’s life or functioning.  
Seriousness, not severity, serves as a guide for defining regulatory obligations.
11.2.3.
Causality 
The Investigator must determine the relationship between the administration of IP and the
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected:
The temporal relationship of the adverse event to IP
administration makes a causal relationship unlikely or 
remote, or other medications, therapeutic interventions, or 
underlying conditions provide a sufficient explanation for the 
observed event.
Suspected:
The temporal relationship of the adverse event to IP
administration makes a causal relationship possible, and other 
medications, therapeutic interventions, or underlying conditions 
do not provide a sufficient explanation for the observed event.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.
11.2.4.
Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
Page 66 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
52
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
11.2.5.
Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(e.g., discontinuation or reduction of IP, as appropriate) and report if concomitant and/or 
additional treatments were given for the event.  
11.2.6.
Outcome
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered, recovered with sequelae, not recovered (death due to another 
cause) or death (due to the SAE).  
11.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:

results in discontinuation from the study;

requires treatment, modification / interruption of IP dose, or any other therapeutic 
intervention; or

is judged to be of significant clinical importance.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page of the CRF.  If the abnormality was not a part of 
a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.
11.4.
Pregnancy
11.4.1.
Females of Childbearing Potential:
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within 112 days of the 
subject’s last dose of IP, are considered immediately reportable events.  The pregnancy, 
suspected pregnancy, or positive pregnancy test must be reported to Celgene Drug Safety
immediately by facsimile, or other appropriate method, using the Pregnancy Initial Report Form, 
or approved equivalent form.  
The female subject may be referred to her obstetrician-gynecologist or another appropriate 
healthcare professional for further evaluation.
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.
If the outcome of the pregnancy was abnormal (e.g., spontaneous or therapeutic abortion), the 
Investigator should report the abnormal outcome as an AE. If the abnormal outcome meets any 
of the serious criteria, it must be reported as an SAE to Celgene Drug Safety immediately by 
facsimile, or other appropriate method, within 24 hours of the Investigator’s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
Page 67 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
53
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 28 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety 
immediately by facsimile, or other appropriate method, within 24 hours of the Investigator’s 
knowledge of the event using the SAE Report Form, or approved equivalent form.
11.4.2.
Male Subjects
If a female partner of a male subject taking IP becomes pregnant, the male subject taking IP 
should notify the Investigator, and the pregnant female partner should be advised to call their 
healthcare provider immediately.  
11.5.
Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page of the CRF.  All SAEs must be reported to Celgene
Drug Safety within 24 hours of the Investigator’s knowledge of the event) by facsimile, or other 
appropriate method, using the SAE Report Form, or approved equivalent form.  This instruction 
pertains to initial SAE reports as well as any follow-up reports.
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
(from the time the subject signs informed consent until at least 42 days after the last dose of IP, 
up to a maximum of 112 days post last dose of IP or until the subject begins a new regimen of 
chemotherapy), and those made known to the Investigator at anytime thereafter that are 
suspected of being related to IP.  Serious adverse events occurring prior to treatment will be 
captured.
The SAE report should provide a detailed description of the SAE and include summaries of 
hospital records and other relevant documents.  If a subject died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data will be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the IRB/EC of 
the SAE and providing them with all relevant initial and follow-up information about the event.  
The Investigator must keep copies of all SAE information on file including correspondence with 
Celgene and the IRB/EC.
11.5.1.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (e.g., missing causality assessment) may be handled by phone.
11.6.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to ACE-011 based on the Investigator Brochure.
Celgene or its authorized representative shall notify the Investigator of the following information
Page 68 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
54
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012

Any AE suspected of being related to the use of IP in this study or in other studies
that is both serious and unexpected (i.e., SUSAR);

Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Celgene and the IRB/EC.  (See Section 15.3 for record retention 
information).
Celgene Drug Safety Contact Information:
For Local Drug Safety Affiliate Office contact information, please refer to the Serious Adverse 
Event Report Form / Completion Guidelines or to the Pregnancy Report Form / Completion 
Guidelines.
Page 69 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
55
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
12.
DISCONTINUATIONS
Treatment Discontinuation
Subjects will be discontinued from study treatment due to the following:

Adverse Event(s)

Hypertension ≥Grade 3 – defined as Stage 2 hypertension (SBP ≥160 mm Hg 
and DBP ≥100 mmHg); medical intervention indicated; initiation of more than 
one drug or more intensive therapy than previously required or medically 
significant hypertension that cannot be adequately controlled with 
antihypertensive therapy

Any AE > Grade 2 assessed to be related to ACE-011 therapy

Any persistent AE > Grade 1 considered to be related to ACE-011 treatment and 
causing a subject to miss three months ACE-011 therapy

Any thromboembolic event > Grade 2

Elevated Hgb > 15.0 g/dL (sustained for a 7-day period, confirmed by laboratory 
assessment)

Lack of ACE-011 therapeutic effect, defined as < 1.0 g/dL increase in Hgb following 
two doses of ACE-011

Withdrawal of consent

Progression of disease

Death

Lost to follow-up

Protocol violation
The reason for discontinuation should be recorded in the CRF and in the source documents.
Study Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the 
study:

Completed study, per protocol

Withdrawal of consent

Death

Lost to follow-up
The following events may be considered sufficient reasons for discontinuing a subject from the 
study:

Adverse events(s)
Page 70 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
56
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012

Progression of disease

Protocol violation
The reason for discontinuation should be recorded in the CRF and in the source documents.  The 
Investigator must notify the Medical Monitor immediately when a subject has been discontinued/ 
withdrawn due to an AE (any unacceptable toxicity).  All subjects who are withdrawn from the 
study should complete the tests and evaluations scheduled for Study Discontinuation at the time 
of withdrawal.
Page 71 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
57
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
13.
EMERGENCY PROCEDURES
13.1.
Emergency Contact
In emergency situations, the Investigator should contact the Celgene Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page).  This global 
Emergency Call Center is available 24 hours a day and 7 days a week.  The representatives are 
responsible for obtaining your call-back information and contacting the on call Celgene/CRO 
Medical Monitor, who will then contact you promptly.
Note:  The back-up 24 hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.  
13.2.
Emergency Identification of Investigational Products
This is an open-label study; therefore, IP will be identified on the package labeling.
Page 72 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
58
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
14.
REGULATORY CONSIDERATIONS
14.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative,
and Investigator abide by Good Clinical Practice (GCP), as described in International 
Conference on Harmonization (ICH) Guideline E6 and in accordance with the general ethical 
principles outlined in the Declaration of Helsinki.  The study will receive approval from an 
IRB/EC prior to commencement.  The Investigator will conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.
14.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions.  
The Investigator should maintain a list of Sub-investigators and other appropriately qualified 
persons to whom he or she has delegated significant study-related duties.
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.
The Investigator, or a designated member of the Investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (e.g., 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The Investigator must ensure timely and accurate completion of CRFs and queries.
14.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a legal representative prior to any study related 
procedures.
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original informed consent document signed and dated by the study 
subject and by the person consenting the study subject prior to the study subject’s entry into the 
study, must be maintained in the Investigator’s study files and a copy given to the study subject.  
In addition, if a protocol is amended and it impacts on the content of the informed consent, the 
informed consent document must be revised.  Study subjects participating in the study when the 
amended protocol is implemented must be re-consented with the revised version of the informed 
consent document.  The revised informed consent document signed and dated by the study 
subject and by the person consenting the study subject must be maintained in the Investigator’s 
study files and a copy given to the study subject.  
Page 73 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
59
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
14.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent).  Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed informed consent document, it is the responsibility of the Investigator to obtain 
such permission in writing from the appropriate individual.
14.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, 
protocol number, study title and amendment number(s) that is applicable.  Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
14.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, informed consent document, and any other 
appropriate documents will be submitted to the IRB/EC with a cover letter or a form listing the 
documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as 
applicable) for which approval is sought.  If applicable, the documents will also be submitted to 
the authorities in accordance with local legal requirements.
Investigational product can only be supplied to an Investigator by Celgene or its authorized 
representative after documentation on all ethical and legal requirements for starting the study has 
been received by Celgene or its authorized representative.  This documentation must also include 
a list of the members of the IRB/EC and their occupation and qualifications.  If the IRB/EC will 
not disclose the names, occupations and qualifications of the committee members, it should be 
asked to issue a statement confirming that the composition of the committee is in accordance 
with GCP.  For example, the IRB General Assurance Number may be accepted as a substitute for 
this list.  Formal approval by the IRB/EC should mention the protocol title, number, amendment 
number (if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed.  It must mention the date on which the decision was made and must be 
officially signed by a committee member.  Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements.  Amendments must be evaluated to 
determine whether formal approval must be sought and whether the informed consent document 
should also be revised.
Page 74 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
60
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC.  This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the
IRB/EC prior to use.  
14.7.
Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:

Information on serious or unexpected adverse events as soon as possible; 

Periodic reports on the progress of the study;

Deviations from the protocol or anything that may involve added risk to subjects.
14.8.
Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons.  Any premature discontinuation will be appropriately documented 
according to local requirements (e.g., IRB/EC, regulatory authorities, etc.).
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:

Unsatisfactory enrollment;

GCP noncompliance;

Inaccurate or incomplete data collection;

Falsification of records;

Failure to adhere to the study protocol.
Page 75 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
61
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
15.
DATA HANDLING AND RECORDKEEPING
15.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed and 
retained.  Examples of source documents include:  hospital records; clinic and office charts; 
laboratory notes; memoranda; subject’s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and 
the laboratories, as well as copies of CRFs or CD-ROM.
15.2.
Data Management
Data will be collected via CRF and entered into the clinical database per Celgene SOPs. This 
data will be electronically verified through use of programmed edit checks specified by the 
clinical team.  Discrepancies in the data will be brought to the attention of the clinical team, and 
investigational site personnel, if necessary.  Resolutions to these issues will be reflected in the 
database.  An audit trail within the system will track all changes made to the data.
15.3.
Record Retention
Essential documents must be retained by the Investigator for a minimum of 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IP.  The investigator must retain these 
documents for the time period described above or according to local laws or requirements, 
whichever is longer.  Essential documents include, but are not limited to, the following:

Signed informed consent documents for all subjects;

Subject identification code list, screening log (if applicable), and enrollment log;

Record of all communications between the Investigator and the IRB/EC;

Composition of the IRB/EC;

Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);

List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;

Copies of CRFs (if paper) and of documentation of corrections for all subjects;

IP accountability records;

Record of any body fluids or tissue samples retained;
Page 76 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
62
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012

All other source documents (subject records, hospital records, laboratory records, 
etc.); 

All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writing from Celgene prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements. Details of these arrangements should be 
documented.  
All study documents should be made available if required by relevant health authorities. 
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.
Page 77 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
63
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
16.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative
for compliance with applicable government regulations with respect to current GCP and standard 
operating procedures.
16.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  Before the study is initiated at a site visit or at an investigator meeting, all aspects of 
the study are reviewed with the Investigator and the staff.  Prior to enrolling subjects into the 
study, a Celgene representative will review the protocol, CRFs, procedures for obtaining 
informed consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring 
will include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone.  At each monitoring visit, the facilities, 
investigational product storage area, CRFs, subject’s source documents, and all other study 
documentation will be inspected/reviewed by the Celgene representative for accuracy, adherence 
to the protocol and Good Clinical Practice.
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the CRFs or via queries by the Investigator and/or his/her 
staff.  Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
16.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Practice 
guidelines and regulations.
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, CRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/IECs, regulatory authorities (e.g. FDA, EMA, Health Canada) and 
company authorized representatives.  The Investigator should make every effort to be available 
for the audits and/or inspections.  If the Investigator is contacted by any regulatory authority 
regarding an inspection, he/she should contact Celgene immediately.
Page 78 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
64
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
17.
PUBLICATIONS
The results of this study may be published in a medical publication, journal, or may be used for
teaching purposes.  Additionally, this study and its results may be submitted for inclusion in all 
appropriate health authority study registries, as well as publication on health authority study
registry websites, as required by local health authority regulations.  Selection of first authorship 
will be based on several considerations, including, but not limited to study participation, 
contribution to the protocol development, and analysis and input into the manuscript, related 
abstracts, and presentations in a study.
Page 79 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
65
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
18.
REFERENCES
Chen Y-G, Lui HM, Lin S-L, Lee JM, and Ying S-Y. Regulation of cell proliferation, apoptosis, 
and carcinogenesis by activin. Exp Biol Med 2002; 227: 75-87.
Lim VS, DeGown RL, Zavala D, et. al. Recombinant human erythropoietin treatment in pre-
dialysis patients.  Annals of Int Med 1989; 110:108-114.
Mathews LS. Activin receptors and cellular signaling by the receptor serine kinase family. 
Endocr Rev 1994; 15: 310-25.
Murata M, Onomichi K, Eto Y, Shibai H, and Muramatsu M. Expression of erythroid 
differentiation factor (EDF) in Chinese hamster ovary cells. Biochem Biophys Res Commun
1988; 151: 230-5.
Nakao K, Kosaka M and Saito S. Effects of erythroid differentiation factor (EDF) on 
proliferation and differentiation of human hematopoietic progenitors. Exp Hematol 1991; 19: 
1090-5.
National Heart, Lung, and Blood Institute, National Institutes of Health. New York Heart 
Association Classification. 2008.
Oken, MM., Creech, R.H., Tormey, D.C., et. al. Toxicity And Response Criteria Of The Eastern 
Cooperative Oncology Group. Am J Clin Onco 1982; 5:649-655.
Perrien DS, Akel NS, Edwards PK, et. al. Inhibin A is an endocrine stimulator of bone mass and 
strength. Endocrinology 2007; 148: 1654-65. 
Rivier J, Spiess J, McClintock R, Vaughan J and Vale W. Purification and partial 
characterization of inhibin from porcine follicular fluid. Biochem Biophys Res Commun 1985; 
133: 120-7.
Ruckle J, Jacobs M, Kramer W, et. al. A single-dose, randomized, double-blind, placebo-
controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res
2009; 24 (4): 744-52.
Shiozaki M, Sakai R, Tabuchi M, et. al. Evidence for the participation of endogenous activin 
A/erythroid differentiation factor in the regulation of erythropoiesis. Proc Natl Acad Sci USA
1992; 89: 1553-6.
Shiozaki M, Sakai R, Tabuchi M, et. al. In vivo treatment with erythroid differentiation factor 
(EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice. Biochem Biophys 
Res Commun 1989; 165: 1155-61.
Woodruff TK. Regulation of cellular and system function by activin. Biochem Pharmacol 1998; 
55: 953-63.
Ying S-Y. Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of 
follicle-stimulating hormone. Endocrine Rev 1988; 9: 267-93.
Page 80 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
66
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
19.
APPENDICES
Appendix A:  ECOG Performance Status Scale
The ECOG scale (Oken, 1982) is used to assess a patient’s quality of life in an evaluation by a 
health professional of the daily activities and how the activities are affected by the disease of the 
patient.
Table 5:
ECOG Performance Status Scale
Score
Description
0
Fully active, able to carry on all pre-disease performance without restriction
1
Restricted in physically strenuous activity but ambulatory and able to carry out work of 
a light or sedentary nature, e.g., light housework, office work.
2
Ambulatory and capable of all self-care but unable to carry out any work activities.  Up 
and about more than 50% of waking hours.
3
Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours.
4
Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair
5
Dead
Page 81 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
67
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Appendix B:  National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.0
Currently active minor version of NCI CTCAE, Version 4.0:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Page 82 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
68
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Appendix C:  New York Heart Association - Classification of Heart Failure
Table 6:
New York Heart Association - Classification of Heart Failure
Class
Symptoms
Class 1
No limitation of activities.  No symptoms from ordinary activities
Class 2
Mild limitation of activity.  Comfortable with rest or mild exertion
Class 3
Marked limitation of activity and be comfortable only at rest
Class 4
Complete rest, confined to bed or chair; any physical activity brings on discomfort and 
symptoms occur at rest
Page 83 of 84
0895R0

Sotatercept (ACE-011)
Protocol ACE-011-ST-001
Celgene Corporation
Confidential and Proprietary
69
ACE-011-ST-001 Amendment 3 FINAL: 05 MAR 2012
Appendix D:  Measurement of Red Blood Cell Mass and Plasma Volume
Principle of Procedure
Polycythemia is a hematologic disorder characterized by an absolute increase in red cell volume 
due to an absolute erythrocytosis.  Primary polycythemia originates in the bone marrow 
(polycythemia vera/myeloproliferative syndrome).  Secondary polycythemia is caused by an 
increase in the production of erythropoietin caused by renal or liver tumors, or high altitude, 
smoking, heart or lung diseases that result in hypoxia.  Both primary and secondary are due to an 
absolute increase in red cell volume or an absolute erythrocytosis.  Some patients have a relative 
erythrocytosis, i.e., an elevated hematocrit due to reduced blood plasma, caused by fluid loss 
e.g., burns, dehydration, etc., so-called stress polycythemia.
The determination of red blood cell volume and plasma volume in these patients is an important 
tool for differentiating absolute from relative polycythemia.  Both the determination of red cell 
volume and plasma volume are by isotope dilution techniques.  Due to the possibility of a 
relative erythrocytosis, the plasma volume should not be calculated from the determined value of 
red cell volume and the venous hematocrit (corrected to the whole body hematocrit).  Plasma 
volume must be determined independently using a second isotopic label.   125I-HSA is used to 
label plasma volume.  125I-HSA rapidly reaches equilibrium and begins immediately to leave the 
vascular space.  Therefore, it is necessary to take specimens at 10, 20 and 30 minutes and 
graphically back extrapolate to time zero to obtain the correct plasma volume.
The label for the red blood cell determination is 51CrO4.  Red blood cells labeled with 51CrO4 do 
not rapidly elute the label, therefore this is the label of choice.  The larger the volume into which 
the label is distributed, the lower the counts will be in samples taken once equilibrium has been 
reached.  Two consecutive samples with count rates that do not vary significantly are taken as 
evidence of attaining equilibrium.  In a normal individual, equilibrium is reached in about 10 
minutes.  The population of patients referred for polycythemia; however, likely include patients 
with splenomegaly and much longer times are required for equilibrium to occur.  Samples for red 
cell volume determination are therefore taken at 30, 60 and 90 minutes.
Procedure
This testing will be performed by a separate laboratory from the study site.  Subjects 
participating in the study will travel to this external laboratory on days where RBC/PV sampling 
will be done (see Table 4).
Page 84 of 84
0895R0